CAP Cancer Protocol Thyroid Gland



Protocol for the Examination of Specimens From Patients With Carcinomas of the Thyroid GlandVersion: Thyroid 4.2.0.0 Protocol Posting Date: August 2019CAP Laboratory Accreditation Program Protocol Required Use Date: May 2020Includes pTNM requirements from the 8th Edition, AJCC Staging ManualFor accreditation purposes, this protocol should be used for the following procedures AND tumor types: ProcedureDescriptionResectionIncludes specimens designated thyroidectomy, lobectomy and partial excisionTumor TypeDescriptionCarcinomaIncludes papillary, follicular, anaplastic, poorly differentiated, and medullary cancersThis protocol is NOT required for accreditation purposes for the following:ProcedureBiopsyPrimary resection specimen with no residual cancer (e.g. following neoadjuvant therapy)Cytologic specimensTumor TypeNoninvasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP)Thyroid carcinomas arising from struma ovariiThyroid carcinomas arising in thyroglossal duct cystsThe following tumor types should NOT be reported using this protocol:Tumor TypeLymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)Sarcoma (consider the Soft Tissue protocol)AuthorsOzgur Mete, MD*; Raja R. Seethala, MD*; Sylvia L. Asa, MD, PhD; Martin J. Bullock, MD; Sally E. Carty, MD; Steven P. Hodak, MD; Jonathan B. McHugh, MD; Yuri E. Nikiforov, MD, PhD; Jason Pettus, MD; Mary S. Richardson, MD, DDS; Jatin Shah, MD; Lester D.R. Thompson, MD With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.* Denotes primary author. All other contributing authors are listed alphabetically.Accreditation RequirementsThis protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format. Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.Optional data elements are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).Synoptic ReportingAll core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:Data element: followed by its answer (response), outline format without the paired "Data element: Response" format is NOT considered synoptic.The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate. Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:Anatomic site or specimen, laterality, and procedurePathologic Stage Classification (pTNM) elementsNegative margins, as long as all negative margins are specifically enumerated where applicableThe synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one locationOrganizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e. all required elements must be in the synoptic portion of the report in the format defined above.Summary of ChangesVersion 4.2.0.0The following data elements were modified:Updated note for reporting multiple tumors of the same cellular lineageNodal Levels InvolvedNodal Levels ExaminedUpdated the Background Documentation for Note B. Tumor SiteSurgical Pathology Cancer Case SummaryProtocol posting date: August 2019THYROID GLAND: Select a single response unless otherwise indicated.Procedure (Note A)___ Total thyroidectomy___ Right lobectomy___ Left lobectomy___ Right partial excision#___ Left partial excision#___ Partial excision# (specify type, if possible): _______________________________ Right lobectomy with isthmusectomy (hemithyroidectomy) ___ Left lobectomy with isthmusectomy (hemithyroidectomy) ___ Right lobe with partial left lobectomy (subtotal or near total thyroidectomy)___ Left lobe with partial right lobectomy (subtotal or near total thyroidectomy)___ Completion thyroidectomy (reoperative)# Anything less than a lobectomy, including substernal excisionTumor Focality (Note B)___ Unifocal___ Multifocal ___ Cannot be determinedFor multiple tumors of the same cellular lineage (eg multifocal papillary carcinoma, follicular carcinoma, etc.), one may choose to repeat the following 9 elements (Tumor Site, Tumor Size, Histologic Type, Margin, Angioinvasion, Lymphatic Invasion, Perineural Invasion, Mitotic Rate and Extra-thyroidal Extension) for clinically relevant tumors. For medullary thyroid carcinoma, please use a separate synoptic report. Tumor Site (select all that apply) (Note B)___ Right lobe___ Left lobe___ Isthmus___ Pyramidal lobe ___ Other (specify): ____________________________Tumor Size (Note C)Greatest dimension (centimeters): ___ cm+ Additional dimensions (centimeters): ___ x ___ cm___ Cannot be determined (explain): ________________________________________Histologic Type (Notes D through H)Papillary Carcinomas___ Papillary carcinoma, classic (usual, conventional)___ Papillary carcinoma, follicular variant, encapsulated/well demarcated, with tumor capsular invasion___ Papillary carcinoma, follicular variant, encapsulated/well demarcated, noninvasive#___ Papillary carcinoma, follicular variant, infiltrative___ Papillary carcinoma, tall cell variant___ Papillary carcinoma, hobnail variant___ Papillary carcinoma, columnar cell variant___ Papillary carcinoma, solid/trabecular variant___ Papillary carcinoma, cribriform-morular variant___ Papillary carcinoma, diffuse sclerosing variant ___ Papillary carcinoma, other variant (specify): _______________________________ Papillary carcinoma# A subset of noninvasive tumors can now be reclassified as NIFTP.+____ Noninvasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP)#### This category is not overtly malignant; reporting is optional and only size, laterality, and margin status are reported.Follicular Carcinomas___ Follicular carcinoma, minimally invasive___ Follicular carcinoma, encapsulated angioinvasive___ Follicular carcinoma, widely invasive___ Follicular carcinoma, minimally invasive, other variant (specify): _______________________________ Follicular carcinoma, encapsulated angioinvasive, other variant (specify): _______________________________ Follicular carcinoma, widely invasive, other variant (specify): _______________________________ Follicular carcinoma, NOSOncocytic (Hürthle cell) Carcinomas___ Oncocytic (Hürthle cell) carcinoma, minimally invasive___ Oncocytic (Hürthle cell) carcinoma, encapsulated angioinvasive___ Oncocytic (Hürthle cell) carcinoma, widely invasivePoorly Differentiated Thyroid Carcinoma___ Poorly differentiated thyroid carcinomaAnaplastic Carcinomas___ Undifferentiated (anaplastic) carcinoma, focal or minor component without extrathyroidal extension___ Undifferentiated (anaplastic) carcinoma, major component___ Undifferentiated (anaplastic) carcinoma, NOSMedullary Carcinomas___ Medullary carcinoma___ Medullary microcarcinoma___ Mixed (composite) medullary carcinoma and follicular epithelial-derived carcinoma (specify): ________________ Carcinoma, type cannot be determined___ Other histologic type not listed (specify): ____________________________Margins (Note I) ___ Cannot be assessed___ Uninvolved by carcinoma + Distance of invasive carcinoma from closest margin (millimeters): ___ mm___ Involved by carcinoma+ Site(s) of involvement: ____________________________Angioinvasion (Vascular Invasion) (Note J)___ Not identified ___ Present+ Extent: + ___ Focal (less than 4 vessels)+ ___ Extensive (4 or more vessels)___ Cannot be determinedLymphatic Invasion (Note J)___ Not identified ___ Present___ Cannot be determined+ Perineural Invasion+___ Not identified +___ Present+___ Cannot be determined+ Mitotic Rate: ____ per 2 mm2Note: Mitoses should be counted in 10 consecutive high-power fields (HPF) at 400x in the most mitotically active area. For most microscopes, 10 HPF is roughly equivalent to 2.5 mm2 Extrathyroidal Extension (Note K) ___ Not identified___ Present, microscopic strap muscle invasion only, with no clinical/macroscopic evidence of invasion___ Present, clinical/macroscopic AND histologically confirmed ___ Invading only strap muscles (ie, pT3b)___ Invading subcutaneous soft tissues, larynx, trachea, esophagus or recurrent laryngeal nerve (ie, pT4a)___ Invading prevertebral fascia or encasing the carotid artery or mediastinal vessels (ie, pT4b)___ Cannot be determinedRegional Lymph Nodes (Note L)___ No lymph nodes submitted or foundLymph Node Examination (required only if lymph nodes present in specimen)Number of Lymph Nodes Involved: _________ Number cannot be determined (explain): ____________________________Lymph Node Metastasis (required only if lymph nodes involved) Nodal Levels Involved (select all apply) ___ Level VI - pretracheal, paratracheal and prelaryngeal/Delphian, perithyroidal (central compartment dissection)___ Level VII (superior mediastinal lymph nodes)___ Right Lateral Level I ___ Right Lateral Level II___ Right Lateral Level III___ Right Lateral Level IV___ Right Lateral Level V___ Left Lateral Level I ___ Left Lateral Level II___ Left Lateral Level III___ Left Lateral Level IV___ Left Lateral Level V___ Other (specify): _______________________________ Cannot be determined (explain): _______________Size of Largest Metastatic Deposit: ___ Specify (centimeters): ____cm ___ Cannot be determined (explain): ______________Extranodal Extension (ENE)___ Not identified ___ Present___ Cannot be determinedNumber of Lymph Nodes Examined: ____Nodal Levels Examined (select all apply)___ Level VI - pretracheal, paratracheal and prelaryngeal/Delphian, perithyroidal (central compartment dissection)___ Level VII (superior mediastinal lymph nodes)___ Right Lateral Level I ___ Right Lateral Level II___ Right Lateral Level III___ Right Lateral Level IV___ Right Lateral Level V___ Left Lateral Level I ___ Left Lateral Level II___ Left Lateral Level III___ Left Lateral Level IV___ Left Lateral Level V___ Other (specify): _______________________________ Cannot be determined (explain): ____________________________Pathologic Stage Classification (pTNM, AJCC 8th Edition) (Note M)Note: Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. Only the applicable T, N, or M category is required for reporting; their definitions need not be included in the report. The categories (with modifiers when applicable) can be listed on 1 line or more than 1 line.TNM Descriptors (required only if applicable) (select all that apply)___ m (multiple primary tumors)___ r (recurrent)___ y (posttreatment)For Papillary, Follicular, Poorly Differentiated, Oncocytic (Hürthle cell) Cell, and Anaplastic Thyroid Carcinoma Primary Tumor (pT) ___ pTX:Primary tumor cannot be assessed___ pT0:No evidence of primary tumor___ pT1:Tumor ≤2 in greatest dimension, limited to the thyroid___ pT1a: Tumor ≤1 cm in greatest dimension limited to the thyroid___ pT1b: Tumor >1 cm but ≤2 cm in greatest dimension, limited to the thyroid___ pT2:Tumor >2 cm, but ≤4 cm in greatest dimension, limited to thyroid___ pT3:Tumor >4 cm limited to the thyroid, or gross extrathyroidal extension invading only strap muscles___ pT3a:Tumor >4 cm limited to the thyroid ___ pT3b:Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size___ pT4:Includes gross extrathyroidal extension beyond the strap muscles___ pT4a:Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size___ pT4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any sizeNote: There is no category of carcinoma in situ (pTis) relative to carcinomas of thyroid gland.For Medullary Thyroid CarcinomaPrimary Tumor (pT) ___ pTX:Primary tumor cannot be assessed___ pT0:No evidence of primary tumor___ pT1:Tumor ≤2 in greatest dimension, limited to the thyroid___ pT1a: Tumor ≤1 cm in greatest dimension limited to the thyroid___ pT1b: Tumor >1 cm but ≤2 cm in greatest dimension, limited to the thyroid___ pT2:Tumor >2 cm, but ≤4 cm in greatest dimension, limited to thyroid___ pT3:Tumor >4 cm or with extrathyroidal extension___ pT3a:Tumor >4 cm in greatest dimension limited to the thyroid ___ pT3b:Tumor of any size with gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid or omohyoid muscles)___pT4: Advanced disease___pT4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve ___pT4b: Very advanced disease; tumor of any size with extension toward the spine or into nearby large blood vessels, gross extrathyroidal extension invading the prevertebral fascia, or encasing the carotid artery or mediastinal vesselsFor All Carcinomas of the ThyroidRegional Lymph Nodes (pN)# ___ pNX:Regional lymph nodes cannot be assessed___ pN0:No evidence of locoregional lymph node metastasis#___ pN0a:One or more cytologically or histologically confirmed benign lymph nodes___ pN1:Metastasis to regional nodes___ pN1a:Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. ___ pN1b:Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes# N0b is defined as no radiologic or clinical evidence of locoregional lymph node metastasis.Distant Metastasis (pM) (required only if confirmed pathologically in this case)___ pM1:Distant metastasisSpecify site(s), if known: ____________________________+ Additional Pathologic Findings (select all that apply)+ ___ Adenoma+ ___ Adenomatoid nodule(s) or nodular follicular disease (eg, nodular hyperplasia, goitrous thyroid)+ ___ Diffuse hyperplasia (Graves disease)+ ___ Thyroiditis (specify type): _____________________+ ___ Parathyroid gland(s) present (specify number, location, and findings): ____________________________+ ___ C-cell hyperplasia (specify type and focality if applicable): __________________________+ ___ None identified+ ___ Other (specify): ____________________________+ Ancillary Studies Note: For reporting molecular testing and other cancer biomarker testing results, the CAP Thyroid Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report. + Clinical History (select all that apply)+ ___ Radiation exposure (specify type): ____________________________+ ___ No known radiation exposure+ ___ Family history of thyroid cancer+ ___ Postoperative serum marker (specify type and result): _________________+ ___ Other (specify): ____________________________+ Comment(s)Explanatory NotesScope of GuidelinesThe reporting of thyroid cancer is facilitated by the provision of a case summary illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a case summary may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the compartments of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Case summaries have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. This case summary tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) Cancer Staging Manual ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1,2</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite><Cite><Author>Rosen</Author><Year>2017</Year><RecNum>46</RecNum><record><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473120927">46</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Rosen, J.E.</author><author>Lloyd, R.V.</author><author>Brierley, J.D.</author><author>Grogan, R.H.</author><author>Haddad, R.</author><author>Hunt, J.L.</author><author>Ridge, J.A.</author><author>Seethala, R.R.</author><author>Sosa, J.A.</author><author>Subramaniam, R.M.</author><author>Wang, T.S.</author><author>Wirth, L.J. </author><author>Perrier, N.D.</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- Medullary</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1,2 and the World Health Organization Classification of Tumours. ADDIN EN.CITE <EndNote><Cite><Author>DeLellis</Author><Year>2004</Year><RecNum>2</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">2</key></foreign-keys><ref-type name="Edited Book">28</ref-type><contributors><authors><author>DeLellis, R.A.</author><author>Lloyd, R.V.</author><author>Heitz, P.U. </author><author>Eng,C</author></authors></contributors><titles><title>Pathology and Genetics of Tumours of the Endocrine Organs</title><secondary-title>World Health Organization Classification of Tumours</secondary-title></titles><dates><year>2004</year></dates><pub-location>Lyons</pub-location><publisher>IARC PRess</publisher><urls></urls></record></Cite></EndNote>3 This protocol is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the thyroid gland in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.References:1.Tuttle RM, Morris LF, Haugen BR, et al. Thyroid- differentiated and anaplastic carcinoma. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.2.Rosen JE, Lloyd RV, Brierley JD, et al. Thyroid-medullary. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.3.Lloyd RV, Osamura RY, Kl?ppel G, Rosai J, eds. Pathology and Genetics of Tumours of the Endocrine Organs. Lyons: IARC PRess; 2017. World Health Organization Classification of Tumours.A. Anatomical Sites of the Thyroid Gland (Figure 1)The thyroid gland ordinarily is composed of a right and a left lobe lying adjacent and lateral to the upper trachea and esophagus. An isthmus connects the 2 lobes, and in some cases a pyramidal lobe is present extending cephalad anterior to the thyroid cartilage. Typically, surgical management of thyroid tumors consists of either a lobe with isthmusectomy (sometimes called hemithyroidectomy) or total thyroidectomy. Cases with lobectomy followed by completion thyroidectomy in the same operative procedure should be classified as total thyroidectomies. Other procedures include subtotal thyroidectomy and level VI central node dissection. Figure 1. Anatomy of the thyroid gland and adjacent structures. From Kini SR. Thyroid Cytopathology: An Atlas and Text. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. Modified with permission.B. Tumor Site The thyroid may give rise to multiple foci of carcinoma in the same gland, designated as per AJCC guidelines with the descriptor “(m).” This protocol is applicable to the dominant excised tumor as well as clinically relevant multifocal tumors. The clinically relevant tumors can be defined as tumors that can impart the tumor stage or dictate patient management during the dynamic risk stratification. For multiple tumors of the same cellular lineage (ie. multifocal papillary carcinoma), characteristics of clinically relevant multifocal tumors can be reported in one synoptic report. In multifocal tumors, the pT stage in the synoptic report is based on the worst findings (collectively) of all the tumors of the same cellular lineage. The features of additional foci that do not necessarily alter management can be detailed under the section on Additional Pathologic Findings. For tumors of different cellular lineage (ie. tumor 1 is papillary thyroid carcinoma and tumor 2 is medullary thyroid carcinoma), a second synoptic report should be generated.C. Tumor SizeTumor size has a significant impact on prognosis and is a component of TNM staging. Papillary carcinomas measuring less than 1 cm are associated with an excellent prognosis, while tumors measuring over 4 cm are associated with a worse prognosis. For follicular carcinomas, tumor size over 3.5 cm is associated with a worse prognosis.1 For medullary carcinomas, size is a staging component, though a recent epidemiologic survey shows that even small tumors (microcarcinomas less than 1.0 cm) have a 20% rate of regional spread and a 5% distant metastatic rate.2References:1.Chan JK. The thyroid gland. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumours. Edinburgh: Churchill Livingstone Elsevier; 2007:1018.2.Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Cancer. 2012;118(3):620-627.D. Histologic TypeThe histologic classification recommended below in notes F through H is modified from the World Health Organization (WHO) published recommendations with a few important alterations based on subsequently published studies.1 This protocol applies only to carcinomas and does not apply to lymphomas, sarcomas, or metastatic tumors to the thyroid gland. WHO Classification of Carcinoma of the ThyroidPapillary carcinomaVariants (in alphabetical order):Classic (usual) Clear cell variant Columnar cell variantCribriform-morular variantDiffuse sclerosing variantFollicular variantHobnail variantMicrocarcinoma (occult, latent, small, microtumor)Oncocytic or oxyphilic variant (follicular variant, nonfollicular variant) Solid/trabecular variantSpindle cell variantTall cell variantWarthin-like variantFollicular carcinomaSubtypes:Minimally invasive Encapsulated angioinvasiveWidely invasiveOncocytic (Hürthle cell) carcinoma#Poorly differentiated thyroid carcinomas including insular carcinomaMedullary carcinomaMixed medullary carcinoma and follicular epithelial derived thyroid carcinomaUndifferentiated (anaplastic) carcinomaCarcinoma, type cannot be determined#Hürthle cell tumors have their own chapter in the 4th edition of the WHO Classification.References:1.DeLellis RA, Lloyd RV, Osamura RY, Kl?ppel G, Rosai JHeitz PU, Eng C, eds. Pathology and Genetics of Tumours of the Endocrine Organs. Lyons: IARC Press; 2017. World Health Organization Classification of Tumours.E. Histologic Grade While AJCC includes a generic 4-tiered scheme for thyroid cancers as with other cancers, application of this to the current classification of thyroid cancers is difficult and not particularly relevant, as there is no grading system beyond what is implied by each specific histologic variant. F. Papillary CarcinomaPapillary carcinoma is the most common carcinoma type and consists of numerous named variants, though only a few of these currently have sufficient evidence to be considered clinically and biologically relevant. Thus effort should be made to flag or document the following variants when present: Classic (usual, conventional)Follicular variant, encapsulated/well demarcatedFollicular variant, infiltrativeTall cell variantHobnail variantCribriform-morular variantDiffuse sclerosing variantClassic (usual, conventional) papillary carcinoma is the most common and “default” variant of papillary carcinoma. Tall cell variant of papillary carcinoma is a more aggressive variant that has a higher prevalence of BRAF mutations and is more frequently refractory to radioactive Iodine therapy.1-3 Hobnail cell variant of papillary carcinoma is an aggressive variant that is characterized by increased frequency of nodal and distant metastatic disease as well as local recurrence.4 The cribriform morular variant is a biologically distinct variant characterized by APC or CTNNB1 mutations and shows an association with familial adenomatous polyposis coli, in some cases preceding recognition of colon polyps or other extracolonic manifestations.5 Diffuse sclerosing variant is a locoregionally aggressive variant with a high rate of nodal metastasis and locoregional recurrence, though overall survival when corrected for other high-risk parameters is not entirely clear. Nonetheless, this variant appears to necessitate more aggressive initial surgical management including extent of node dissection.6 Follicular variant of papillary carcinoma is important to document because it has recently been substratified based on outcome into noninvasive (encapsulated/well demarcated) and infiltrative follicular variants. Unencapsulated infiltrative follicular variants have a behavior similar to classic papillary carcinoma, particularly in terms of propensity for nodal metastasis, while the behavior of encapsulated follicular variant is more indolent.7,8 Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) A subset of noninvasive follicular variants of papillary thyroid carcinoma is currently classified under the new designation noninvasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP). This shift in nomenclature arose as an effort to encourage conservative management of these lesions given their extremely low risk of structural and chemical recurrence.9 NIFTP is still not entirely considered benign and remains an actionable surgical disease, albeit with a more conservative approach. As NIFTP is not overtly malignant, it is technically not required to report these under this cancer protocol. However, it is encouraged to report these, though only limited parameters are relevant, namely size, laterality, and margin status.It must be noted that not all tumors previously designated as noninvasive follicular variant of papillary thyroid carcinoma would qualify as NIFTP.9 Main inclusion criteria require that the tumor is: Encapsulated or well demarcated Follicular patternedDemonstrating at least focal nuclear features of papillary thyroid carcinoma Another key requirement for this designation is that the entire lesional border has been submitted for histologic evaluation. However, several exclusionary criteria exist as well in order to ensure that the NIFTP category remains indolent and are as follows9: Infiltration/tumoral capsular invasion.Solid/trabecular or insular growth greater than 30%True papillary growth (with fibrovascular cores) (even 1 well-formed papillary structure)Psammoma bodiesTall cell, hobnail cell, columnar cell, or cribriform morular morphologyNecrosisMitoses greater than 3 per 10 consecutive high power fields (HPF) (in solid/microfollicular areas)When a tumor fulfills these inclusion and exclusion criteria, NIFTP designation is appropriate. Of note, NIFTP is not well-validated in oncocytic, sub-centimeter, and multifocal lesions. In these scenarios, the designation NIFTP is not absolutely contraindicated but there are inadequate data to substantiate this designation. It must be emphasized that in order for NIFTP to accurately reflect an indolent tumor type, rigorous application of the inclusion and exclusion criteria should be employed – specifically complete submission of tumor normal interface, adequate sampling of the tumor center (ie, at least 1 section per centimeter of tumor) and strict observation of histologic criteria. NIFTP is still an evolving diagnosis, and certain problematic areas have already been noted. For instance, it is challenging to evaluate for invasion in well-circumscribed unencapsulated tumors. The recommendation for qualification as NIFTP in this scenario is to demonstrate a complete rim of compressed thyroid parenchyma with absolutely no mingling of normal and neoplastic follicles. Another problematic area is recognition of exclusionary papillae. A papilla in this context is well formed, demonstrates a fibrovascular core (unlike the follicles seen in Sanderson’s polster), and shows overt nuclear features of papillary carcinoma. Initial criterion of less than 1%9 is noted to be subjective and difficult to apply. Additionally, this cut-off was already shown to be inferior to a 0% cut-off in ensuring indolent outcome. Thus even 1 well-formed papilla as defined above should be considered exclusionary.Other variants that may have prognostic and therapeutic value but are rare and not well validated include: Clear cellColumnar cellMacrofollicularOncocytic or oxyphilicSolid/trabecular Warthin-likePapillary microcarcinomas (also historically referred to as papillary microtumor, occult, latent, or small papillary carcinoma) are not technically a specific variant but refer to papillary carcinomas that are found incidentally measuring 1 cm or less.4 In spite of their rather common identification in thyroid gland resections10,11PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Lb21vcm93c2tpPC9BdXRob3I+PFllYXI+MTk4ODwvWWVh

cj48UmVjTnVtPjEzPC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNjcmlw

dCI+MTQsMTU8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xMzwvcmVj

LW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InBzMnd3ZHNmcmEycjVl

ZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIxNDczMTE3MTM3Ij4xMzwva2V5Pjwv

Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlw

ZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S29tb3Jvd3NraSwgUi4gQS48L2F1dGhv

cj48YXV0aG9yPkhhbnNvbiwgRy4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+

PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBhdGhvbG9neSwgTWVkaWNhbCBDb2xsZWdlIG9m

IFdpc2NvbnNpbiwgTWlsd2F1a2VlIDUzMjI2LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxl

Pk9jY3VsdCB0aHlyb2lkIHBhdGhvbG9neSBpbiB0aGUgeW91bmcgYWR1bHQ6IGFuIGF1dG9wc3kg

c3R1ZHkgb2YgMTM4IHBhdGllbnRzIHdpdGhvdXQgY2xpbmljYWwgdGh5cm9pZCBkaXNlYXNlPC90

aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkh1bSBQYXRob2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxl

cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5IdW0gUGF0aG9sPC9mdWxsLXRpdGxlPjwvcGVyaW9k

aWNhbD48cGFnZXM+Njg5LTk2PC9wYWdlcz48dm9sdW1lPjE5PC92b2x1bWU+PG51bWJlcj42PC9u

dW1iZXI+PGVkaXRpb24+MTk4OC8wNi8wMTwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QWRl

bm9tYS9kaWFnbm9zaXMvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3Jk

PjxrZXl3b3JkPkNhcmNpbm9tYSwgUGFwaWxsYXJ5L2RpYWdub3Npcy9wYXRob2xvZ3k8L2tleXdv

cmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZpYnJvc2lzL3BhdGhvbG9neTwv

a2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+THltcGhvY3l0ZXMvcGF0

aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+VGh5cm9pZCBE

aXNlYXNlcy9kaWFnbm9zaXMvKnBhdGhvbG9neTwva2V5d29yZD48a2V5d29yZD5UaHlyb2lkIEds

YW5kLypwYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VGh5cm9pZCBOZW9wbGFzbXMvZGlhZ25v

c2lzL3BhdGhvbG9neS9zZWNvbmRhcnk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+

MTk4ODwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVz

Pjxpc2JuPjAwNDYtODE3NyAoUHJpbnQpJiN4RDswMDQ2LTgxNzcgKExpbmtpbmcpPC9pc2JuPjxh

Y2Nlc3Npb24tbnVtPjMzNzg3ODg8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48

dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzM3ODc4ODwvdXJsPjwvcmVs

YXRlZC11cmxzPjwvdXJscz48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+

PENpdGU+PEF1dGhvcj5GaW5rPC9BdXRob3I+PFllYXI+MTk5NjwvWWVhcj48UmVjTnVtPjE0PC9S

ZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxr

ZXkgYXBwPSJFTiIgZGItaWQ9InBzMnd3ZHNmcmEycjVlZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIg

dGltZXN0YW1wPSIxNDczMTE3MTM3Ij4xNDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBu

YW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3Jz

PjxhdXRob3I+RmluaywgQS48L2F1dGhvcj48YXV0aG9yPlRvbWxpbnNvbiwgRy48L2F1dGhvcj48

YXV0aG9yPkZyZWVtYW4sIEouIEwuPC9hdXRob3I+PGF1dGhvcj5Sb3NlbiwgSS4gQi48L2F1dGhv

cj48YXV0aG9yPkFzYSwgUy4gTC48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1

dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBhdGhvbG9neSwgTW91bnQgU2luYWkgSG9zcGl0YWws

IFVuaXZlcnNpdHkgb2YgVG9yb250bywgT250YXJpbywgQ2FuYWRhLjwvYXV0aC1hZGRyZXNzPjx0

aXRsZXM+PHRpdGxlPk9jY3VsdCBtaWNyb3BhcGlsbGFyeSBjYXJjaW5vbWEgYXNzb2NpYXRlZCB3

aXRoIGJlbmlnbiBmb2xsaWN1bGFyIHRoeXJvaWQgZGlzZWFzZSBhbmQgdW5yZWxhdGVkIHRoeXJv

aWQgbmVvcGxhc21zPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPk1vZCBQYXRob2w8L3NlY29uZGFy

eS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Nb2QgUGF0aG9sPC9mdWxs

LXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+ODE2LTIwPC9wYWdlcz48dm9sdW1lPjk8L3ZvbHVt

ZT48bnVtYmVyPjg8L251bWJlcj48ZWRpdGlvbj4xOTk2LzA4LzAxPC9lZGl0aW9uPjxrZXl3b3Jk

cz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxr

ZXl3b3JkPkFnZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdv

cmQ+QWdlZCwgODAgYW5kIG92ZXI8L2tleXdvcmQ+PGtleXdvcmQ+Q2FyY2lub21hLCBQYXBpbGxh

cnkvZXBpZGVtaW9sb2d5LypwYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdvcmQ+

PGtleXdvcmQ+TG9naXN0aWMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+

PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IEZhY3RvcnM8L2tleXdv

cmQ+PGtleXdvcmQ+VGh5cm9pZCBEaXNlYXNlcy8qcGF0aG9sb2d5L3N1cmdlcnk8L2tleXdvcmQ+

PGtleXdvcmQ+VGh5cm9pZCBOZW9wbGFzbXMvZXBpZGVtaW9sb2d5LypwYXRob2xvZ3k8L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk5NjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkF1

ZzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjA4OTMtMzk1MiAoUHJpbnQpJiN4RDsw

ODkzLTM5NTIgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjg4NzE5MjI8L2FjY2Vzc2lv

bi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdv

di9wdWJtZWQvODg3MTkyMjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48bGFuZ3VhZ2U+ZW5n

PC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Lb21vcm93c2tpPC9BdXRob3I+PFllYXI+MTk4ODwvWWVh

cj48UmVjTnVtPjEzPC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNjcmlw

dCI+MTQsMTU8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xMzwvcmVj

LW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InBzMnd3ZHNmcmEycjVl

ZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIxNDczMTE3MTM3Ij4xMzwva2V5Pjwv

Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlw

ZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S29tb3Jvd3NraSwgUi4gQS48L2F1dGhv

cj48YXV0aG9yPkhhbnNvbiwgRy4gQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+

PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBhdGhvbG9neSwgTWVkaWNhbCBDb2xsZWdlIG9m

IFdpc2NvbnNpbiwgTWlsd2F1a2VlIDUzMjI2LjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxl

Pk9jY3VsdCB0aHlyb2lkIHBhdGhvbG9neSBpbiB0aGUgeW91bmcgYWR1bHQ6IGFuIGF1dG9wc3kg

c3R1ZHkgb2YgMTM4IHBhdGllbnRzIHdpdGhvdXQgY2xpbmljYWwgdGh5cm9pZCBkaXNlYXNlPC90

aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkh1bSBQYXRob2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxl

cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5IdW0gUGF0aG9sPC9mdWxsLXRpdGxlPjwvcGVyaW9k

aWNhbD48cGFnZXM+Njg5LTk2PC9wYWdlcz48dm9sdW1lPjE5PC92b2x1bWU+PG51bWJlcj42PC9u

dW1iZXI+PGVkaXRpb24+MTk4OC8wNi8wMTwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QWRl

bm9tYS9kaWFnbm9zaXMvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3Jk

PjxrZXl3b3JkPkNhcmNpbm9tYSwgUGFwaWxsYXJ5L2RpYWdub3Npcy9wYXRob2xvZ3k8L2tleXdv

cmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZpYnJvc2lzL3BhdGhvbG9neTwv

a2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+THltcGhvY3l0ZXMvcGF0

aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+VGh5cm9pZCBE

aXNlYXNlcy9kaWFnbm9zaXMvKnBhdGhvbG9neTwva2V5d29yZD48a2V5d29yZD5UaHlyb2lkIEds

YW5kLypwYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VGh5cm9pZCBOZW9wbGFzbXMvZGlhZ25v

c2lzL3BhdGhvbG9neS9zZWNvbmRhcnk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+

MTk4ODwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVz

Pjxpc2JuPjAwNDYtODE3NyAoUHJpbnQpJiN4RDswMDQ2LTgxNzcgKExpbmtpbmcpPC9pc2JuPjxh

Y2Nlc3Npb24tbnVtPjMzNzg3ODg8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48

dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzM3ODc4ODwvdXJsPjwvcmVs

YXRlZC11cmxzPjwvdXJscz48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+

PENpdGU+PEF1dGhvcj5GaW5rPC9BdXRob3I+PFllYXI+MTk5NjwvWWVhcj48UmVjTnVtPjE0PC9S

ZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxr

ZXkgYXBwPSJFTiIgZGItaWQ9InBzMnd3ZHNmcmEycjVlZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIg

dGltZXN0YW1wPSIxNDczMTE3MTM3Ij4xNDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBu

YW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3Jz

PjxhdXRob3I+RmluaywgQS48L2F1dGhvcj48YXV0aG9yPlRvbWxpbnNvbiwgRy48L2F1dGhvcj48

YXV0aG9yPkZyZWVtYW4sIEouIEwuPC9hdXRob3I+PGF1dGhvcj5Sb3NlbiwgSS4gQi48L2F1dGhv

cj48YXV0aG9yPkFzYSwgUy4gTC48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1

dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBhdGhvbG9neSwgTW91bnQgU2luYWkgSG9zcGl0YWws

IFVuaXZlcnNpdHkgb2YgVG9yb250bywgT250YXJpbywgQ2FuYWRhLjwvYXV0aC1hZGRyZXNzPjx0

aXRsZXM+PHRpdGxlPk9jY3VsdCBtaWNyb3BhcGlsbGFyeSBjYXJjaW5vbWEgYXNzb2NpYXRlZCB3

aXRoIGJlbmlnbiBmb2xsaWN1bGFyIHRoeXJvaWQgZGlzZWFzZSBhbmQgdW5yZWxhdGVkIHRoeXJv

aWQgbmVvcGxhc21zPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPk1vZCBQYXRob2w8L3NlY29uZGFy

eS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Nb2QgUGF0aG9sPC9mdWxs

LXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+ODE2LTIwPC9wYWdlcz48dm9sdW1lPjk8L3ZvbHVt

ZT48bnVtYmVyPjg8L251bWJlcj48ZWRpdGlvbj4xOTk2LzA4LzAxPC9lZGl0aW9uPjxrZXl3b3Jk

cz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxr

ZXl3b3JkPkFnZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdv

cmQ+QWdlZCwgODAgYW5kIG92ZXI8L2tleXdvcmQ+PGtleXdvcmQ+Q2FyY2lub21hLCBQYXBpbGxh

cnkvZXBpZGVtaW9sb2d5LypwYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdvcmQ+

PGtleXdvcmQ+TG9naXN0aWMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+

PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IEZhY3RvcnM8L2tleXdv

cmQ+PGtleXdvcmQ+VGh5cm9pZCBEaXNlYXNlcy8qcGF0aG9sb2d5L3N1cmdlcnk8L2tleXdvcmQ+

PGtleXdvcmQ+VGh5cm9pZCBOZW9wbGFzbXMvZXBpZGVtaW9sb2d5LypwYXRob2xvZ3k8L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk5NjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkF1

ZzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjA4OTMtMzk1MiAoUHJpbnQpJiN4RDsw

ODkzLTM5NTIgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjg4NzE5MjI8L2FjY2Vzc2lv

bi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdv

di9wdWJtZWQvODg3MTkyMjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48bGFuZ3VhZ2U+ZW5n

PC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE.DATA and apparent indolent biologic behavior, it is the recommendation to issue a protocol for all cases in which papillary thyroid carcinoma is found, including subcentimeter carcinomas, whether incidentally found in a thyroid gland removed for other reasons (eg, multinodular goiter), discovered clinically (palpable, visible nodule), and/or discovered by imaging. Given the more sophisticated diagnostic (eg, imaging) modalities currently available, small (ie, less than 1 cm) lesions are being identified and resected. In an effort to have these papillary microcarcinomas reported and documented in tumor registries, thereby providing for long-term follow-up and better determination of their biologic nature, it is recommended that they should also be reported following this CAP thyroid protocol. More recently, certain histologic features have been shown to correlate with nodal metastasis in papillary microcarcinomas. A combined histologic-molecular scoring scheme has been proposed for microcarcinomas based on BRAF mutation status, subcapsular location, peri- and intratumoral fibrosis, and multifocality. This is not yet validated, but documentations of the aforementioned morphologic parameters (with or without mutational status) may be useful in management. ADDIN EN.CITE <EndNote><Cite><Author>Niemeier</Author><Year>2012</Year><RecNum>64</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117137">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Niemeier, L. A.</author><author>Kuffner Akatsu, H.</author><author>Song, C.</author><author>Carty, S. E.</author><author>Hodak, S. P.</author><author>Yip, L.</author><author>Ferris, R. L.</author><author>Tseng, G. C.</author><author>Seethala, R. R.</author><author>Lebeau, S. O.</author><author>Stang, M. T.</author><author>Coyne, C.</author><author>Johnson, J. T.</author><author>Stewart, A. F.</author><author>Nikiforov, Y. E.</author></authors></contributors><auth-address>Department of Pathology and Laboratory Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.</auth-address><titles><title>A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma</title><secondary-title>Cancer</secondary-title></titles><periodical><full-title>Cancer</full-title></periodical><pages>2069-77</pages><volume>118</volume><number>8</number><edition>2011/09/02</edition><keywords><keyword>Carcinoma</keyword><keyword>Humans</keyword><keyword>Lymphatic Metastasis</keyword><keyword>*Mutation</keyword><keyword>Proto-Oncogene Proteins B-raf/*genetics</keyword><keyword>Recurrence</keyword><keyword>Risk Assessment/*methods</keyword><keyword>Thyroid Neoplasms/*genetics/*pathology</keyword></keywords><dates><year>2012</year><pub-dates><date>Apr 15</date></pub-dates></dates><isbn>1097-0142 (Electronic)&#xD;0008-543X (Linking)</isbn><accession-num>21882177</accession-num><urls><related-urls><url> References:1.Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20(2):153-158.2.Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569-580.3.Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113(1):48-56.4.DeLellis RA, Lloyd RV, Osamura RY, Kl?ppel G, Rosai JHeitz PU, Eng C, eds. Pathology and Genetics of Tumours of the Endocrine Organs. Lyons: IARC PRess; 201704. World Health Organization Classification of Tumours.5.Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol. 1999;12(4):400-411.6.Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. 2011;21(4):383-389.7.Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA. Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid. 2009;19(2):119-127.8.Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006;107(6):1255-1264.9.Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA oncology. 2016;2(8):1023-1029.10.Komorowski RA, Hanson GA. Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol. 1988;19(6):689-696.11.Fink A, Tomlinson G, Freeman JL, Rosen IB, Asa SL. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod Pathol. 1996;9(8):816-820.12.Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118(8):2069-2077.G. Follicular CarcinomaFollicular carcinoma is a well-differentiated carcinoma type defined by invasiveness in the absence of diagnostic nuclear features of papillary thyroid carcinoma. The diagnosis of follicular carcinoma and its distinction from follicular adenoma primarily depends on the identification of invasion of the tumor capsule and/or vascular spaces (see also note I).A few cytomorphological variants of follicular carcinomas defined in the past include oncocytic (Hürthle cell) variant, clear cell variant, mucinous variant, and follicular carcinoma with signet-ring cells. Historically oncocytic carcinoma was considered a distinct entity. Even now the debate continues among experts as to whether this tumor is sufficiently biologically distinct as to warrant categorization as a separate entity. This variant is often more aggressive and radioactive iodine resistant. However, when controlled for stage and extent of invasion, this difference is diminished. ADDIN EN.CITE <EndNote><Cite><Author>Nikiforov</Author><Year>2012</Year><RecNum>16</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117137">16</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Nikiforov, Y. E.</author><author>Ohori, N. P.</author></authors><secondary-authors><author>Nikiforov, Y. E.</author><author>Biddinger, P.W.</author><author>Thompson, L.D.R.</author></secondary-authors></contributors><titles><title>Follicular carcinoma</title><secondary-title>Diagnostic pathology and molecular genetics of the thyroid</secondary-title></titles><pages>152-182</pages><edition>2nd</edition><section>10</section><dates><year>2012</year></dates><pub-location>Philadelphia</pub-location><publisher>Lippincott Williams and Wilkins</publisher><urls></urls></record></Cite></EndNote>1 Nevertheless, oncocytic (Hürthle cell) carcinomas have now their own chapter in the 4th edition of the WHO classification. The 4th edition of the WHO classification subtyped follicular carcinoma as follows:-Minimally invasive follicular carcinoma -Encapsulated angioinvasive follicular carcinoma-Widely invasive follicular carcinomaCriteria for Tumor Capsular InvasionWhile conceptually simple, there is no consensus as to the definition of the tumor capsular invasion. Some authorities require complete transgression of the capsule, while other authorities do not require complete transgression of the capsule. Figure 2 depicts the various histologic appearances for the presence or absence of capsular invasion. While a number of the illustrated representations of capsular invasion would be accepted by all pathologists (eg, C, D, E, H), other depictions listed as “Not yet” (eg, F, G, I) may be acceptable to some pathologists as representing capsular invasion. The use of multiple levels can assist the diagnosis of the tumor capsular invasion. The impact of previous biopsy may confound the interpretation of capsular invasion and must be considered.22286006604000Figure 2. Tumor Capsular invasion (CI). Schematic drawing for the interpretation of the presence or absence of CI. The diagram depicts a follicular neoplasm (orange) surrounded by a fibrous capsule (green). A. Bosselation on the inner aspect of the capsule does not represent CI. B. Sharp tumor bud invades into but not through the capsule suggesting invasion requiring deeper sections to exclude. C. Tumor totally transgresses the capsule invading beyond the outer contour of the capsule qualifying as CI. D. Tumor clothed by thin (probably new) fibrous capsule but already extending beyond an imaginary (dotted) line drawn through the outer contour of the capsule qualifying as CI. E. Satellite tumor nodule with similar features (architecture, cytomorphology) to the main tumor lying outside the capsule qualifying as CI. F. Follicles aligned perpendicular to the capsule suggesting invasion requiring deeper sections to exclude. G. Follicles aligned parallel to the capsule do not represent CI. H. Mushroom-shaped tumor with total transgression of the capsule qualifies as CI. I. Mushroom-shaped tumor within but not through the capsule suggests invasion requiring deeper sections to exclude invasion. J. Neoplastic follicles in the fibrous capsule with a degenerated appearance accompanied by lymphocytes and siderophages does not represent CI but rather capsular rupture related to prior fine-needle aspiration.From Fletcher CDM, ed. Diagnostic Histopathology of Tumours. 3rd ed. Edinburgh: Churchill Livingstone Elsevier; 2007. Modified with permission. ? Elsevier.The criteria defining minimally invasive follicular carcinoma are controversial. The 4th edition of the WHO classification now separates encapsulated angioinvasive tumors into a distinct more aggressive category than minimally invasive carcinoma. Literature supports this separation.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OaWtpZm9yb3Y8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFy

PjxSZWNOdW0+MTY8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0

Ij4xNywxODwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjE2PC9yZWMt

bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0icHMyd3dkc2ZyYTJyNWVl

OXphc3hzNXQ4endkd3hyc3dlNXhhIiB0aW1lc3RhbXA9IjE0NzMxMTcxMzciPjE2PC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkJvb2sgU2VjdGlvbiI+NTwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5pa2lmb3JvdiwgWS4gRS48L2F1dGhvcj48YXV0

aG9yPk9ob3JpLCBOLiBQLjwvYXV0aG9yPjwvYXV0aG9ycz48c2Vjb25kYXJ5LWF1dGhvcnM+PGF1

dGhvcj5OaWtpZm9yb3YsIFkuIEUuPC9hdXRob3I+PGF1dGhvcj5CaWRkaW5nZXIsIFAuVy48L2F1

dGhvcj48YXV0aG9yPlRob21wc29uLCBMLkQuUi48L2F1dGhvcj48L3NlY29uZGFyeS1hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkZvbGxpY3VsYXIgY2FyY2lub21hPC90aXRs

ZT48c2Vjb25kYXJ5LXRpdGxlPkRpYWdub3N0aWMgcGF0aG9sb2d5IGFuZCBtb2xlY3VsYXIgZ2Vu

ZXRpY3Mgb2YgdGhlIHRoeXJvaWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGFnZXM+MTUy

LTE4MjwvcGFnZXM+PGVkaXRpb24+Mm5kPC9lZGl0aW9uPjxzZWN0aW9uPjEwPC9zZWN0aW9uPjxk

YXRlcz48eWVhcj4yMDEyPC95ZWFyPjwvZGF0ZXM+PHB1Yi1sb2NhdGlvbj5QaGlsYWRlbHBoaWE8

L3B1Yi1sb2NhdGlvbj48cHVibGlzaGVyPkxpcHBpbmNvdHQgV2lsbGlhbXMgYW5kIFdpbGtpbnM8

L3B1Ymxpc2hlcj48dXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+dmFu

IEhlZXJkZW48L0F1dGhvcj48WWVhcj4xOTkyPC9ZZWFyPjxSZWNOdW0+MTc8L1JlY051bT48cmVj

b3JkPjxyZWMtbnVtYmVyPjE3PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0icHMyd3dkc2ZyYTJyNWVlOXphc3hzNXQ4endkd3hyc3dlNXhhIiB0aW1lc3RhbXA9

IjE0NzMxMTcxMzciPjE3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu

YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj52

YW4gSGVlcmRlbiwgSi4gQS48L2F1dGhvcj48YXV0aG9yPkhheSwgSS4gRC48L2F1dGhvcj48YXV0

aG9yPkdvZWxsbmVyLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+U2Fsb21hbywgRC48L2F1dGhvcj48

YXV0aG9yPkViZXJzb2xkLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+QmVyZ3N0cmFsaCwgRS4gSi48

L2F1dGhvcj48YXV0aG9yPkdyYW50LCBDLiBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1

dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgU3VyZ2VyeSwgTWF5byBDbGluaWMsIFJv

Y2hlc3RlciwgTU4gNTU5MDUuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+Rm9sbGljdWxh

ciB0aHlyb2lkIGNhcmNpbm9tYSB3aXRoIGNhcHN1bGFyIGludmFzaW9uIGFsb25lOiBhIG5vbnRo

cmVhdGVuaW5nIG1hbGlnbmFuY3k8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+U3VyZ2VyeTwvc2Vj

b25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPlN1cmdlcnk8L2Z1

bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xMTMwLTY7IGRpc2N1c3Npb24gMTEzNi04PC9w

YWdlcz48dm9sdW1lPjExMjwvdm9sdW1lPjxudW1iZXI+NjwvbnVtYmVyPjxlZGl0aW9uPjE5OTIv

MTIvMDE8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkZW5vY2FyY2lub21hLypwYXRob2xv

Z3kvc3VyZ2VyeTwva2V5d29yZD48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2Vk

PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQsIDgwIGFuZCBvdmVyPC9rZXl3b3JkPjxrZXl3b3JkPkZl

bWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5

d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5NdWx0aXZhcmlhdGUg

QW5hbHlzaXM8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gSW52YXNpdmVuZXNzPC9rZXl3b3Jk

PjxrZXl3b3JkPlBvc3RvcGVyYXRpdmUgUGVyaW9kPC9rZXl3b3JkPjxrZXl3b3JkPlRoeXJvaWQg

TmVvcGxhc21zLypwYXRob2xvZ3kvc3VyZ2VyeTwva2V5d29yZD48a2V5d29yZD5UcmVhdG1lbnQg

T3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTkyPC95ZWFyPjxwdWIt

ZGF0ZXM+PGRhdGU+RGVjPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDAzOS02MDYw

IChQcmludCkmI3hEOzAwMzktNjA2MCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTQ1

NTMxNTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5u

Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8xNDU1MzE1PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxz

PjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4wMDM5LTYwNjAoOTIpOTAzMTgtVCBbcGlpXTwvZWxl

Y3Ryb25pYy1yZXNvdXJjZS1udW0+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9D

aXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OaWtpZm9yb3Y8L0F1dGhvcj48WWVhcj4yMDEyPC9ZZWFy

PjxSZWNOdW0+MTY8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0

Ij4xNywxODwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjE2PC9yZWMt

bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0icHMyd3dkc2ZyYTJyNWVl

OXphc3hzNXQ4endkd3hyc3dlNXhhIiB0aW1lc3RhbXA9IjE0NzMxMTcxMzciPjE2PC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkJvb2sgU2VjdGlvbiI+NTwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5pa2lmb3JvdiwgWS4gRS48L2F1dGhvcj48YXV0

aG9yPk9ob3JpLCBOLiBQLjwvYXV0aG9yPjwvYXV0aG9ycz48c2Vjb25kYXJ5LWF1dGhvcnM+PGF1

dGhvcj5OaWtpZm9yb3YsIFkuIEUuPC9hdXRob3I+PGF1dGhvcj5CaWRkaW5nZXIsIFAuVy48L2F1

dGhvcj48YXV0aG9yPlRob21wc29uLCBMLkQuUi48L2F1dGhvcj48L3NlY29uZGFyeS1hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkZvbGxpY3VsYXIgY2FyY2lub21hPC90aXRs

ZT48c2Vjb25kYXJ5LXRpdGxlPkRpYWdub3N0aWMgcGF0aG9sb2d5IGFuZCBtb2xlY3VsYXIgZ2Vu

ZXRpY3Mgb2YgdGhlIHRoeXJvaWQ8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGFnZXM+MTUy

LTE4MjwvcGFnZXM+PGVkaXRpb24+Mm5kPC9lZGl0aW9uPjxzZWN0aW9uPjEwPC9zZWN0aW9uPjxk

YXRlcz48eWVhcj4yMDEyPC95ZWFyPjwvZGF0ZXM+PHB1Yi1sb2NhdGlvbj5QaGlsYWRlbHBoaWE8

L3B1Yi1sb2NhdGlvbj48cHVibGlzaGVyPkxpcHBpbmNvdHQgV2lsbGlhbXMgYW5kIFdpbGtpbnM8

L3B1Ymxpc2hlcj48dXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+dmFu

IEhlZXJkZW48L0F1dGhvcj48WWVhcj4xOTkyPC9ZZWFyPjxSZWNOdW0+MTc8L1JlY051bT48cmVj

b3JkPjxyZWMtbnVtYmVyPjE3PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0icHMyd3dkc2ZyYTJyNWVlOXphc3hzNXQ4endkd3hyc3dlNXhhIiB0aW1lc3RhbXA9

IjE0NzMxMTcxMzciPjE3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu

YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj52

YW4gSGVlcmRlbiwgSi4gQS48L2F1dGhvcj48YXV0aG9yPkhheSwgSS4gRC48L2F1dGhvcj48YXV0

aG9yPkdvZWxsbmVyLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+U2Fsb21hbywgRC48L2F1dGhvcj48

YXV0aG9yPkViZXJzb2xkLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+QmVyZ3N0cmFsaCwgRS4gSi48

L2F1dGhvcj48YXV0aG9yPkdyYW50LCBDLiBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1

dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgU3VyZ2VyeSwgTWF5byBDbGluaWMsIFJv

Y2hlc3RlciwgTU4gNTU5MDUuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+Rm9sbGljdWxh

ciB0aHlyb2lkIGNhcmNpbm9tYSB3aXRoIGNhcHN1bGFyIGludmFzaW9uIGFsb25lOiBhIG5vbnRo

cmVhdGVuaW5nIG1hbGlnbmFuY3k8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+U3VyZ2VyeTwvc2Vj

b25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPlN1cmdlcnk8L2Z1

bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xMTMwLTY7IGRpc2N1c3Npb24gMTEzNi04PC9w

YWdlcz48dm9sdW1lPjExMjwvdm9sdW1lPjxudW1iZXI+NjwvbnVtYmVyPjxlZGl0aW9uPjE5OTIv

MTIvMDE8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkFkZW5vY2FyY2lub21hLypwYXRob2xv

Z3kvc3VyZ2VyeTwva2V5d29yZD48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2Vk

PC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQsIDgwIGFuZCBvdmVyPC9rZXl3b3JkPjxrZXl3b3JkPkZl

bWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5

d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5NdWx0aXZhcmlhdGUg

QW5hbHlzaXM8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gSW52YXNpdmVuZXNzPC9rZXl3b3Jk

PjxrZXl3b3JkPlBvc3RvcGVyYXRpdmUgUGVyaW9kPC9rZXl3b3JkPjxrZXl3b3JkPlRoeXJvaWQg

TmVvcGxhc21zLypwYXRob2xvZ3kvc3VyZ2VyeTwva2V5d29yZD48a2V5d29yZD5UcmVhdG1lbnQg

T3V0Y29tZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTkyPC95ZWFyPjxwdWIt

ZGF0ZXM+PGRhdGU+RGVjPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDAzOS02MDYw

IChQcmludCkmI3hEOzAwMzktNjA2MCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTQ1

NTMxNTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5u

Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8xNDU1MzE1PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxz

PjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4wMDM5LTYwNjAoOTIpOTAzMTgtVCBbcGlpXTwvZWxl

Y3Ryb25pYy1yZXNvdXJjZS1udW0+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9D

aXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA 1,3 Even 1 focus of angioinvasion places a tumor into this new category. Thus, minimally invasive carcinomas are now restricted to tumoral capsular invasion only. Widely invasive follicular carcinomas have similarly nebulous definition and consist of those tumors with grossly apparent invasion of thyroid and/or soft tissue (ie, extrathyroidal invasion).4 The term is usually assigned to tumors with loss of encapsulation and multiple fronts of tumor invasion radiating from the epicenter of the tumor. These tumors are typically accompanied by other markers of aggressiveness such as extrathyroidal extension and extensive vascular invasion. References:1.Nikiforov YE, Ohori NP. Follicular carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR, eds. Diagnostic Pathology and Molecular Genetics of the Thyroid. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2012:152-182.2.Chan JK. The thyroid gland. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumours. Edinburgh: Churchill Livingstone Elsevier; 2007:1018.3.van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery. 1992;112(6):1130-1136; discussion 1136-1138.4.DeLellis RA, Lloyd RV, Osamura RY, Kl?ppel G, Rosai JHeitz PU, Eng C, eds. Pathology and Genetics of Tumours of the Endocrine Organs. Lyons: IARC Press; 2017. World Health Organization Classification of Tumours.H. Poorly Differentiated and Undifferentiated (Anaplastic) CarcinomaWhile the majority of thyroid cancers are well differentiated, a subset are poorly differentiated (historically known as insular, or trabecular, carcinoma) or undifferentiated (anaplastic). These tumor types represent progression to a more aggressive phenotype and are often seen with co-existent or antecedent well-differentiated carcinoma. While detailed histomorphologic review is beyond the scope of this protocol, salient features of both tumor types are listed below. Briefly, poorly differentiated carcinomas are tumors that display a solid, trabecular, and/or insular growth pattern, and show 1 or more of the following: greater than 3 mitoses per 10 HPF, necrosis, and nuclear convolution (without other features seen in papillary carcinoma).PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Wb2xhbnRlPC9BdXRob3I+PFllYXI+MjAwNzwvWWVhcj48

UmVjTnVtPjE4PC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+

MTk8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xODwvcmVjLW51bWJl

cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InBzMnd3ZHNmcmEycjVlZTl6YXN4

czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIxNDczMTE3MTM3Ij4xODwva2V5PjwvZm9yZWln

bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29u

dHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+Vm9sYW50ZSwgTS48L2F1dGhvcj48YXV0aG9yPkNv

bGxpbmksIFAuPC9hdXRob3I+PGF1dGhvcj5OaWtpZm9yb3YsIFkuIEUuPC9hdXRob3I+PGF1dGhv

cj5TYWthbW90bywgQS48L2F1dGhvcj48YXV0aG9yPktha3VkbywgSy48L2F1dGhvcj48YXV0aG9y

PkthdG9oLCBSLjwvYXV0aG9yPjxhdXRob3I+TGxveWQsIFIuIFYuPC9hdXRob3I+PGF1dGhvcj5M

aVZvbHNpLCBWLiBBLjwvYXV0aG9yPjxhdXRob3I+UGFwb3R0aSwgTS48L2F1dGhvcj48YXV0aG9y

PlNvYnJpbmhvLVNpbW9lcywgTS48L2F1dGhvcj48YXV0aG9yPkJ1c3NvbGF0aSwgRy48L2F1dGhv

cj48YXV0aG9yPlJvc2FpLCBKLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0

aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgQ2xpbmljYWwgYW5kIEJpb2xvZ2ljYWwgU2NpZW5jZXMg

YXQgU2FuIEx1aWdpIEhvc3BpdGFsLCBVbml2ZXJzaXR5IG9mIFR1cmluLCBUdXJpbiwgSXRhbHku

IG1hcmNvLnZvbGFudGVAdW5pdG8uaXQ8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Qb29y

bHkgZGlmZmVyZW50aWF0ZWQgdGh5cm9pZCBjYXJjaW5vbWE6IHRoZSBUdXJpbiBwcm9wb3NhbCBm

b3IgdGhlIHVzZSBvZiB1bmlmb3JtIGRpYWdub3N0aWMgY3JpdGVyaWEgYW5kIGFuIGFsZ29yaXRo

bWljIGRpYWdub3N0aWMgYXBwcm9hY2g8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0gSiBTdXJn

IFBhdGhvbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxl

PkFtIEogU3VyZyBQYXRob2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xMjU2LTY0

PC9wYWdlcz48dm9sdW1lPjMxPC92b2x1bWU+PG51bWJlcj44PC9udW1iZXI+PGVkaXRpb24+MjAw

Ny8wOC8wMjwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QWRlbm9jYXJjaW5vbWEvY2hlbWlz

dHJ5L2NsYXNzaWZpY2F0aW9uLypkaWFnbm9zaXMvbW9ydGFsaXR5PC9rZXl3b3JkPjxrZXl3b3Jk

PkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdl

ZDwva2V5d29yZD48a2V5d29yZD5BZ2VkLCA4MCBhbmQgb3Zlcjwva2V5d29yZD48a2V5d29yZD4q

QWxnb3JpdGhtczwva2V5d29yZD48a2V5d29yZD5DZWxsIE51Y2xldXMvcGF0aG9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkLCBQcmVzY2hvb2w8L2tl

eXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD5JbW11bm9oaXN0b2NoZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk1pdG9zaXM8L2tleXdv

cmQ+PGtleXdvcmQ+TmVjcm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5

d29yZD48a2V5d29yZD5UaHlyb2lkIE5lb3BsYXNtcy9jaGVtaXN0cnkvY2xhc3NpZmljYXRpb24v

KmRpYWdub3Npcy9tb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+VHVtb3IgTWFya2VycywgQmlv

bG9naWNhbC9hbmFseXNpczwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDA3PC95

ZWFyPjxwdWItZGF0ZXM+PGRhdGU+QXVnPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+

MDE0Ny01MTg1IChQcmludCkmI3hEOzAxNDctNTE4NSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lv

bi1udW0+MTc2Njc1NTE8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0

dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMTc2Njc1NTE8L3VybD48L3JlbGF0ZWQt

dXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwOTcvUEFTLjBiMDEzZTMx

ODAzMDllNmEmI3hEOzAwMDAwNDc4LTIwMDcwODAwMC0wMDAxNyBbcGlpXTwvZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Wb2xhbnRlPC9BdXRob3I+PFllYXI+MjAwNzwvWWVhcj48

UmVjTnVtPjE4PC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+

MTk8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xODwvcmVjLW51bWJl

cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InBzMnd3ZHNmcmEycjVlZTl6YXN4

czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIxNDczMTE3MTM3Ij4xODwva2V5PjwvZm9yZWln

bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29u

dHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+Vm9sYW50ZSwgTS48L2F1dGhvcj48YXV0aG9yPkNv

bGxpbmksIFAuPC9hdXRob3I+PGF1dGhvcj5OaWtpZm9yb3YsIFkuIEUuPC9hdXRob3I+PGF1dGhv

cj5TYWthbW90bywgQS48L2F1dGhvcj48YXV0aG9yPktha3VkbywgSy48L2F1dGhvcj48YXV0aG9y

PkthdG9oLCBSLjwvYXV0aG9yPjxhdXRob3I+TGxveWQsIFIuIFYuPC9hdXRob3I+PGF1dGhvcj5M

aVZvbHNpLCBWLiBBLjwvYXV0aG9yPjxhdXRob3I+UGFwb3R0aSwgTS48L2F1dGhvcj48YXV0aG9y

PlNvYnJpbmhvLVNpbW9lcywgTS48L2F1dGhvcj48YXV0aG9yPkJ1c3NvbGF0aSwgRy48L2F1dGhv

cj48YXV0aG9yPlJvc2FpLCBKLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0

aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgQ2xpbmljYWwgYW5kIEJpb2xvZ2ljYWwgU2NpZW5jZXMg

YXQgU2FuIEx1aWdpIEhvc3BpdGFsLCBVbml2ZXJzaXR5IG9mIFR1cmluLCBUdXJpbiwgSXRhbHku

IG1hcmNvLnZvbGFudGVAdW5pdG8uaXQ8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Qb29y

bHkgZGlmZmVyZW50aWF0ZWQgdGh5cm9pZCBjYXJjaW5vbWE6IHRoZSBUdXJpbiBwcm9wb3NhbCBm

b3IgdGhlIHVzZSBvZiB1bmlmb3JtIGRpYWdub3N0aWMgY3JpdGVyaWEgYW5kIGFuIGFsZ29yaXRo

bWljIGRpYWdub3N0aWMgYXBwcm9hY2g8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0gSiBTdXJn

IFBhdGhvbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxl

PkFtIEogU3VyZyBQYXRob2w8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4xMjU2LTY0

PC9wYWdlcz48dm9sdW1lPjMxPC92b2x1bWU+PG51bWJlcj44PC9udW1iZXI+PGVkaXRpb24+MjAw

Ny8wOC8wMjwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QWRlbm9jYXJjaW5vbWEvY2hlbWlz

dHJ5L2NsYXNzaWZpY2F0aW9uLypkaWFnbm9zaXMvbW9ydGFsaXR5PC9rZXl3b3JkPjxrZXl3b3Jk

PkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdl

ZDwva2V5d29yZD48a2V5d29yZD5BZ2VkLCA4MCBhbmQgb3Zlcjwva2V5d29yZD48a2V5d29yZD4q

QWxnb3JpdGhtczwva2V5d29yZD48a2V5d29yZD5DZWxsIE51Y2xldXMvcGF0aG9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkLCBQcmVzY2hvb2w8L2tl

eXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD5JbW11bm9oaXN0b2NoZW1pc3RyeTwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk1pdG9zaXM8L2tleXdv

cmQ+PGtleXdvcmQ+TmVjcm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+U3Vydml2YWwgUmF0ZTwva2V5

d29yZD48a2V5d29yZD5UaHlyb2lkIE5lb3BsYXNtcy9jaGVtaXN0cnkvY2xhc3NpZmljYXRpb24v

KmRpYWdub3Npcy9tb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+VHVtb3IgTWFya2VycywgQmlv

bG9naWNhbC9hbmFseXNpczwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDA3PC95

ZWFyPjxwdWItZGF0ZXM+PGRhdGU+QXVnPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+

MDE0Ny01MTg1IChQcmludCkmI3hEOzAxNDctNTE4NSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lv

bi1udW0+MTc2Njc1NTE8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0

dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMTc2Njc1NTE8L3VybD48L3JlbGF0ZWQt

dXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwOTcvUEFTLjBiMDEzZTMx

ODAzMDllNmEmI3hEOzAwMDAwNDc4LTIwMDcwODAwMC0wMDAxNyBbcGlpXTwvZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE.DATA 1 As noted above, poorly differentiated thyroid carcinoma may be seen as a component of well-differentiated carcinoma, and as little as 10% of a poorly differentiated component is sufficient to confer an aggressive biologic behavior. ADDIN EN.CITE <EndNote><Cite><Author>Dettmer</Author><Year>2011</Year><RecNum>19</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117137">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dettmer, M.</author><author>Schmitt, A.</author><author>Steinert, H.</author><author>Haldemann, A.</author><author>Meili, A.</author><author>Moch, H.</author><author>Komminoth, P.</author><author>Perren, A.</author></authors></contributors><auth-address>Institute of Pathology, University of Bern, Triemlispital, Zurich. dettmerms@upmc.edu</auth-address><titles><title>Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed?</title><secondary-title>Am J Surg Pathol</secondary-title></titles><periodical><full-title>Am J Surg Pathol</full-title></periodical><pages>1866-72</pages><volume>35</volume><number>12</number><edition>2011/10/13</edition><keywords><keyword>Adenocarcinoma, Follicular/pathology</keyword><keyword>Carcinoma, Papillary/pathology</keyword><keyword>*Cell Differentiation</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Kaplan-Meier Estimate</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Staging</keyword><keyword>Prognosis</keyword><keyword>Proportional Hazards Models</keyword><keyword>Thyroid Neoplasms/mortality/*pathology</keyword></keywords><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1532-0979 (Electronic)&#xD;0147-5185 (Linking)</isbn><accession-num>21989341</accession-num><urls><related-urls><url> On the other hand, encapsulated tumors appear to have a more favorable prognosis than unencapsulated tumors, particularly if they show no capsular or vascular invasion with adequate sampling.3,4 Undifferentiated carcinoma represents the most extreme form of tumor progression and consists of a high-grade malignancy with spindled, pleomorphic, squamoid, or even rhabdoid morphology. 5 Undifferentiated carcinoma is almost invariably rapidly lethal. The few exceptions are noteworthy as they mainly consist of well-differentiated tumor with only focal anaplastic transformation.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdWdpdGFuaTwvQXV0aG9yPjxZZWFyPjIwMDE8L1llYXI+

PFJlY051bT4yMzwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQi

PjIzLTI1PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MjM8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwczJ3d2RzZnJhMnI1ZWU5

emFzeHM1dDh6d2R3eHJzd2U1eGEiIHRpbWVzdGFtcD0iMTQ3MzExNzEzNyI+MjM8L2tleT48L2Zv

cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+

PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlN1Z2l0YW5pLCBJLjwvYXV0aG9yPjxhdXRo

b3I+S2FzYWksIE4uPC9hdXRob3I+PGF1dGhvcj5GdWppbW90bywgWS48L2F1dGhvcj48YXV0aG9y

PllhbmFnaXNhd2EsIEEuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFk

ZHJlc3M+RGl2aXNpb24gb2YgSGVhZCBhbmQgTmVjaywgQ2FuY2VyIEluc3RpdHV0ZSBIb3NwaXRh

bCwgMS0zNy0xIEthbWktaWtlYnVrdXJvLCBUb3NoaW1hLWt1LCBUb2t5byAxNzAtODQ1NSwgSmFw

YW4uIGl3YW8tc3VnQHRjNC5zby1uZXQubmUuanA8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRs

ZT5Qcm9nbm9zdGljIGZhY3RvcnMgYW5kIHRoZXJhcGV1dGljIHN0cmF0ZWd5IGZvciBhbmFwbGFz

dGljIGNhcmNpbm9tYSBvZiB0aGUgdGh5cm9pZDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5Xb3Js

ZCBKIFN1cmc8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5Xb3JsZCBKIFN1cmc8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz42MTctMjI8L3Bh

Z2VzPjx2b2x1bWU+MjU8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48ZWRpdGlvbj4yMDAxLzA1

LzIzPC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5B

Z2VkPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQsIDgwIGFuZCBvdmVyPC9rZXl3b3JkPjxrZXl3b3Jk

PkNvbWJpbmVkIE1vZGFsaXR5IFRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5

d29yZD5Qcm9wb3J0aW9uYWwgSGF6YXJkcyBNb2RlbHM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBG

YWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlN1cnZpdmFsIEFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3

b3JkPlRoeXJvaWQgTmVvcGxhc21zLyptb3J0YWxpdHkvKnRoZXJhcHk8L2tleXdvcmQ+PC9rZXl3

b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMTwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heTwvZGF0ZT48

L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAzNjQtMjMxMyAoUHJpbnQpJiN4RDswMzY0LTIzMTMg

KExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExMzY5OTg5PC9hY2Nlc3Npb24tbnVtPjx1

cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVk

LzExMzY5OTg5PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNl

LW51bT4xMC4xMDA3L3MwMDI2ODAwMjAxNjY8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxsYW5n

dWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkFsZGluZ2Vy

PC9BdXRob3I+PFllYXI+MTk3ODwvWWVhcj48UmVjTnVtPjI0PC9SZWNOdW0+PHJlY29yZD48cmVj

LW51bWJlcj4yNDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9

InBzMnd3ZHNmcmEycjVlZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIxNDczMTE3

MTM4Ij4yNDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGlj

bGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QWxkaW5nZXIs

IEsuIEEuPC9hdXRob3I+PGF1dGhvcj5TYW1hYW4sIE4uIEEuPC9hdXRob3I+PGF1dGhvcj5JYmFu

ZXosIE0uPC9hdXRob3I+PGF1dGhvcj5IaWxsLCBDLiBTLiwgSnIuPC9hdXRob3I+PC9hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkFuYXBsYXN0aWMgY2FyY2lub21hIG9mIHRo

ZSB0aHlyb2lkOiBhIHJldmlldyBvZiA4NCBjYXNlcyBvZiBzcGluZGxlIGFuZCBnaWFudCBjZWxs

IGNhcmNpbm9tYSBvZiB0aGUgdGh5cm9pZDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5DYW5jZXI8

L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5DYW5jZXI8

L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4yMjY3LTc1PC9wYWdlcz48dm9sdW1lPjQx

PC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGVkaXRpb24+MTk3OC8wNi8wMTwvZWRpdGlvbj48

a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5BbmFwbGFzaWEvcGF0aG9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNhcmNpbm9tYS9ldGlvbG9neS8qcGF0aG9sb2d5L3RoZXJh

cHk8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBEaWZmZXJlbnRpYXRpb248L2tleXdvcmQ+PGtleXdv

cmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxl

PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Np

czwva2V5d29yZD48a2V5d29yZD5UaHlyb2lkIE5lb3BsYXNtcy9ldGlvbG9neS8qcGF0aG9sb2d5

L3RoZXJhcHk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk3ODwveWVhcj48cHVi

LWRhdGVzPjxkYXRlPkp1bjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDgtNTQz

WCAoUHJpbnQpJiN4RDswMDA4LTU0M1ggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjY1

NzA5MTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5u

Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC82NTcwOTE8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+

PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+Tmlr

aWZvcm92PC9BdXRob3I+PFllYXI+MjAxMjwvWWVhcj48UmVjTnVtPjIyPC9SZWNOdW0+PHJlY29y

ZD48cmVjLW51bWJlcj4yMjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIg

ZGItaWQ9InBzMnd3ZHNmcmEycjVlZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIx

NDczMTE3MTM3Ij4yMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJCb29rIFNl

Y3Rpb24iPjU8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OaWtpZm9y

b3YsIFkuIEUuPC9hdXRob3I+PGF1dGhvcj5TZWV0aGFsYSwgUi4gUi48L2F1dGhvcj48L2F1dGhv

cnM+PHNlY29uZGFyeS1hdXRob3JzPjxhdXRob3I+TmlraWZvcm92LCBZLiBFLjwvYXV0aG9yPjxh

dXRob3I+QmlkZGluZ2VyLCBQLlcuPC9hdXRob3I+PGF1dGhvcj5UaG9tcHNvbiwgTC5ELlIuPC9h

dXRob3I+PC9zZWNvbmRhcnktYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5B

bmFwbGFzdGljICh1bmRpZmZlcmVudGlhdGVkKSBjYXJjaW5vbWE8L3RpdGxlPjxzZWNvbmRhcnkt

dGl0bGU+RGlhZ25vc3RpYyBwYXRob2xvZ3kgYW5kIG1vbGVjdWxhciBnZW5ldGljcyBvZiB0aGUg

dGh5cm9pZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwYWdlcz4yNjMtMjg0PC9wYWdlcz48

ZWRpdGlvbj4ybmQ8L2VkaXRpb24+PHNlY3Rpb24+MTA8L3NlY3Rpb24+PGRhdGVzPjx5ZWFyPjIw

MTI8L3llYXI+PC9kYXRlcz48cHViLWxvY2F0aW9uPlBoaWxhZGVscGhpYTwvcHViLWxvY2F0aW9u

PjxwdWJsaXNoZXI+TGlwcGluY290dCBXaWxsaWFtcyBhbmQgV2lsa2luczwvcHVibGlzaGVyPjx1

cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdWdpdGFuaTwvQXV0aG9yPjxZZWFyPjIwMDE8L1llYXI+

PFJlY051bT4yMzwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQi

PjIzLTI1PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MjM8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwczJ3d2RzZnJhMnI1ZWU5

emFzeHM1dDh6d2R3eHJzd2U1eGEiIHRpbWVzdGFtcD0iMTQ3MzExNzEzNyI+MjM8L2tleT48L2Zv

cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+

PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlN1Z2l0YW5pLCBJLjwvYXV0aG9yPjxhdXRo

b3I+S2FzYWksIE4uPC9hdXRob3I+PGF1dGhvcj5GdWppbW90bywgWS48L2F1dGhvcj48YXV0aG9y

PllhbmFnaXNhd2EsIEEuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFk

ZHJlc3M+RGl2aXNpb24gb2YgSGVhZCBhbmQgTmVjaywgQ2FuY2VyIEluc3RpdHV0ZSBIb3NwaXRh

bCwgMS0zNy0xIEthbWktaWtlYnVrdXJvLCBUb3NoaW1hLWt1LCBUb2t5byAxNzAtODQ1NSwgSmFw

YW4uIGl3YW8tc3VnQHRjNC5zby1uZXQubmUuanA8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRs

ZT5Qcm9nbm9zdGljIGZhY3RvcnMgYW5kIHRoZXJhcGV1dGljIHN0cmF0ZWd5IGZvciBhbmFwbGFz

dGljIGNhcmNpbm9tYSBvZiB0aGUgdGh5cm9pZDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5Xb3Js

ZCBKIFN1cmc8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5Xb3JsZCBKIFN1cmc8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz42MTctMjI8L3Bh

Z2VzPjx2b2x1bWU+MjU8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48ZWRpdGlvbj4yMDAxLzA1

LzIzPC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5B

Z2VkPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQsIDgwIGFuZCBvdmVyPC9rZXl3b3JkPjxrZXl3b3Jk

PkNvbWJpbmVkIE1vZGFsaXR5IFRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5

d29yZD5Qcm9wb3J0aW9uYWwgSGF6YXJkcyBNb2RlbHM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBG

YWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlN1cnZpdmFsIEFuYWx5c2lzPC9rZXl3b3JkPjxrZXl3

b3JkPlRoeXJvaWQgTmVvcGxhc21zLyptb3J0YWxpdHkvKnRoZXJhcHk8L2tleXdvcmQ+PC9rZXl3

b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMTwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heTwvZGF0ZT48

L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAzNjQtMjMxMyAoUHJpbnQpJiN4RDswMzY0LTIzMTMg

KExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExMzY5OTg5PC9hY2Nlc3Npb24tbnVtPjx1

cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVk

LzExMzY5OTg5PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNl

LW51bT4xMC4xMDA3L3MwMDI2ODAwMjAxNjY8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxsYW5n

dWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkFsZGluZ2Vy

PC9BdXRob3I+PFllYXI+MTk3ODwvWWVhcj48UmVjTnVtPjI0PC9SZWNOdW0+PHJlY29yZD48cmVj

LW51bWJlcj4yNDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9

InBzMnd3ZHNmcmEycjVlZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIxNDczMTE3

MTM4Ij4yNDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGlj

bGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QWxkaW5nZXIs

IEsuIEEuPC9hdXRob3I+PGF1dGhvcj5TYW1hYW4sIE4uIEEuPC9hdXRob3I+PGF1dGhvcj5JYmFu

ZXosIE0uPC9hdXRob3I+PGF1dGhvcj5IaWxsLCBDLiBTLiwgSnIuPC9hdXRob3I+PC9hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkFuYXBsYXN0aWMgY2FyY2lub21hIG9mIHRo

ZSB0aHlyb2lkOiBhIHJldmlldyBvZiA4NCBjYXNlcyBvZiBzcGluZGxlIGFuZCBnaWFudCBjZWxs

IGNhcmNpbm9tYSBvZiB0aGUgdGh5cm9pZDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5DYW5jZXI8

L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5DYW5jZXI8

L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4yMjY3LTc1PC9wYWdlcz48dm9sdW1lPjQx

PC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGVkaXRpb24+MTk3OC8wNi8wMTwvZWRpdGlvbj48

a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29yZD5BbmFwbGFzaWEvcGF0aG9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNhcmNpbm9tYS9ldGlvbG9neS8qcGF0aG9sb2d5L3RoZXJh

cHk8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBEaWZmZXJlbnRpYXRpb248L2tleXdvcmQ+PGtleXdv

cmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxl

PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Np

czwva2V5d29yZD48a2V5d29yZD5UaHlyb2lkIE5lb3BsYXNtcy9ldGlvbG9neS8qcGF0aG9sb2d5

L3RoZXJhcHk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk3ODwveWVhcj48cHVi

LWRhdGVzPjxkYXRlPkp1bjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDgtNTQz

WCAoUHJpbnQpJiN4RDswMDA4LTU0M1ggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjY1

NzA5MTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5u

Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC82NTcwOTE8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+

PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+Tmlr

aWZvcm92PC9BdXRob3I+PFllYXI+MjAxMjwvWWVhcj48UmVjTnVtPjIyPC9SZWNOdW0+PHJlY29y

ZD48cmVjLW51bWJlcj4yMjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIg

ZGItaWQ9InBzMnd3ZHNmcmEycjVlZTl6YXN4czV0OHp3ZHd4cnN3ZTV4YSIgdGltZXN0YW1wPSIx

NDczMTE3MTM3Ij4yMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJCb29rIFNl

Y3Rpb24iPjU8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OaWtpZm9y

b3YsIFkuIEUuPC9hdXRob3I+PGF1dGhvcj5TZWV0aGFsYSwgUi4gUi48L2F1dGhvcj48L2F1dGhv

cnM+PHNlY29uZGFyeS1hdXRob3JzPjxhdXRob3I+TmlraWZvcm92LCBZLiBFLjwvYXV0aG9yPjxh

dXRob3I+QmlkZGluZ2VyLCBQLlcuPC9hdXRob3I+PGF1dGhvcj5UaG9tcHNvbiwgTC5ELlIuPC9h

dXRob3I+PC9zZWNvbmRhcnktYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5B

bmFwbGFzdGljICh1bmRpZmZlcmVudGlhdGVkKSBjYXJjaW5vbWE8L3RpdGxlPjxzZWNvbmRhcnkt

dGl0bGU+RGlhZ25vc3RpYyBwYXRob2xvZ3kgYW5kIG1vbGVjdWxhciBnZW5ldGljcyBvZiB0aGUg

dGh5cm9pZDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwYWdlcz4yNjMtMjg0PC9wYWdlcz48

ZWRpdGlvbj4ybmQ8L2VkaXRpb24+PHNlY3Rpb24+MTA8L3NlY3Rpb24+PGRhdGVzPjx5ZWFyPjIw

MTI8L3llYXI+PC9kYXRlcz48cHViLWxvY2F0aW9uPlBoaWxhZGVscGhpYTwvcHViLWxvY2F0aW9u

PjxwdWJsaXNoZXI+TGlwcGluY290dCBXaWxsaWFtcyBhbmQgV2lsa2luczwvcHVibGlzaGVyPjx1

cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA 5-7 These tumors are treatable surgically and will have a more favorable prognosis than a predominantly anaplastic carcinoma. Thus, tumors with only focal anaplastic areas and no extrathyroidal extension should be delineated from the more common and overtly anaplastic tumors. The maximum percentage of tumor that is allowable by the term focal in this context is unclear at this point, however, and will require judgment on a case-by-case basis.References:1.Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256-1264.2.Dettmer M, Schmitt A, Steinert H, et al. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am J Surg Pathol. 2011;35(12):1866-1872.3.Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006;106(6):1286-1295.4.Rivera M, Ricarte-Filho J, Patel S, et al. Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol. 2010;41(2):172-180.5.Nikiforov YE, Seethala RR. Anaplastic (undifferentiated) carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR, eds. Diagnostic Pathology and Molecular Genetics of the Thyroid. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2012:263-284.6.Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25(5):617-622.7.Aldinger KA, Samaan NA, Ibanez M, Hill CS, Jr. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer. 1978;41(6):2267-2275.I. MarginsBy convention, margin status is a required data element in association with thyroid cancers. The “margin” is defined as the surface of the thyroid specimen, usually the outer aspect of the thyroid gland and/or inked edge of the specimen. The evaluation of the relationship of tumor to the inked edge of the tissue represents determination of margin status. It should be noted that the thyroid “capsule” is not an anatomically defined structure. Evidence has shown that microscopically the capsule is focally incomplete or absent in a majority of thyroid glands evaluated at autopsy. ADDIN EN.CITE <EndNote><Cite><Author>Komorowski</Author><Year>1988</Year><RecNum>13</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117137">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Komorowski, R. A.</author><author>Hanson, G. A.</author></authors></contributors><auth-address>Department of Pathology, Medical College of Wisconsin, Milwaukee 53226.</auth-address><titles><title>Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease</title><secondary-title>Hum Pathol</secondary-title></titles><periodical><full-title>Hum Pathol</full-title></periodical><pages>689-96</pages><volume>19</volume><number>6</number><edition>1988/06/01</edition><keywords><keyword>Adenoma/diagnosis/pathology</keyword><keyword>Adult</keyword><keyword>Carcinoma, Papillary/diagnosis/pathology</keyword><keyword>Female</keyword><keyword>Fibrosis/pathology</keyword><keyword>Humans</keyword><keyword>Lymphocytes/pathology</keyword><keyword>Male</keyword><keyword>Thyroid Diseases/diagnosis/*pathology</keyword><keyword>Thyroid Gland/*pathology</keyword><keyword>Thyroid Neoplasms/diagnosis/pathology/secondary</keyword></keywords><dates><year>1988</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>0046-8177 (Print)&#xD;0046-8177 (Linking)</isbn><accession-num>3378788</accession-num><urls><related-urls><url> Further, unlike hollow organs such as the gastrointestinal tract where there is continuity of the entire viscera such that a real surgical and pathologic margin exists, the same does not hold true for the thyroid gland such that tumor at the margin (ie, capsule and/or ink) does not correlate to incomplete excision. Few published studies have addressed the influence of margin status and patient outcome. Most surgeons, endocrinologists, and nuclear medicine specialists request information on margin status. While this makes intuitive sense, and it is recommended that a positive margin be mentioned in the final pathology report, meticulous studies on the effect of positive margins and outcome in large series of patients with long-term follow-up are lacking. Indeed, there is no data to date on the prognostic value of close margins as an independent or co-variable.References:1.Komorowski RA, Hanson GA. Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol. 1988;19(6):689-696.J. Angioinvasion (Vascular Invasion) and Lymphatic InvasionAngiolymphatic invasion is an important parameter for both papillary and follicular carcinomas. Given the preferential spread of papillary carcinoma via lymphatics and follicular carcinoma via hematogenous routes, the vessels invaded by papillary carcinoma are usually lymphatic spaces and those in follicular carcinoma are usually blood vessels. However, papillary carcinomas can involve vascular spaces, as indicated by occasional hematogenous spread. Thus, the distinction between vascular and lymphatic invasion is required in that the former is a predictor of a more aggressive pattern of spread. Criteria for Angioinvasion As noted above, papillary thyroid carcinomas tend to spread via lymphatics. In addition to tumor deposits within lymphatic spaces, this form of spread may manifest as psammoma bodies alone within these spaces, which are the equivalent of lymphatic invasion for reporting purposes.For encapsulated follicular carcinomas, criteria are designed to identify venous vascular invasion, as this is the typical means of spread for these tumors. Vascular invasion can be a diagnostic criterion for follicular carcinoma and appears to correlate with poor outcome. As with capsular invasion, vascular invasion, though conceptually straightforward, is controversial and challenging. For vascular invasion, the blood vessels should be located outside the tumor, within the capsule, or outside the capsule. 1 The involved spaces should include capsular or extracapsular vessels. While angioinvasion of a venous caliber space is fairly easily recognized, occasionally separating capillary sized vascular spaces from lymphatics may be difficult. Morphologically smaller vascular spaces will still have red blood cells within. In challenging cases, markers selective for vascular and lymphatic endothelium, such as CD31 and podoplanin (D2-40), respectively, may be useful. ADDIN EN.CITE <EndNote><Cite><Author>Mete</Author><Year>2011</Year><RecNum>22</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117138">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mete, O.</author><author>Asa, S. L.</author></authors></contributors><auth-address>Department of Pathology, University Health Network, Toronto, Ontario, Canada. Ozgur.Mete2@uhn.on.ca</auth-address><titles><title>Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation</title><secondary-title>Mod Pathol</secondary-title></titles><periodical><full-title>Mod Pathol</full-title></periodical><pages>1545-52</pages><volume>24</volume><number>12</number><edition>2011/08/02</edition><keywords><keyword>Adenocarcinoma, Follicular</keyword><keyword>Artifacts</keyword><keyword>Autopsy</keyword><keyword>Biopsy</keyword><keyword>Blood Vessels/*pathology</keyword><keyword>Carcinoma</keyword><keyword>Cell Differentiation</keyword><keyword>Epithelial Cells/*pathology</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Retrospective Studies</keyword><keyword>Thyroid Neoplasms/*pathology/secondary</keyword><keyword>Time Factors</keyword></keywords><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1530-0285 (Electronic)&#xD;0893-3952 (Linking)</isbn><accession-num>21804527</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 Figure 3 depicts the various histologic appearances of vascular invasion. 3 The minimal requirements for clinically meaningful vascular invasion are currently a point of controversy. Historically, the presence of endothelialized tumor alone has been the minimal criterion to identify vascular space invasion, a finding supported in the literature. 1 More recently, however, 1 group has raised the caveat that tumor cells within vascular lumina unassociated with thrombus, and tumor cells underlying intact endothelium could represent “pseudoinvasion” given the fenestrated endothelial network of endocrine organs. ADDIN EN.CITE <EndNote><Cite><Author>Mete</Author><Year>2011</Year><RecNum>22</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117138">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mete, O.</author><author>Asa, S. L.</author></authors></contributors><auth-address>Department of Pathology, University Health Network, Toronto, Ontario, Canada. Ozgur.Mete2@uhn.on.ca</auth-address><titles><title>Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation</title><secondary-title>Mod Pathol</secondary-title></titles><periodical><full-title>Mod Pathol</full-title></periodical><pages>1545-52</pages><volume>24</volume><number>12</number><edition>2011/08/02</edition><keywords><keyword>Adenocarcinoma, Follicular</keyword><keyword>Artifacts</keyword><keyword>Autopsy</keyword><keyword>Biopsy</keyword><keyword>Blood Vessels/*pathology</keyword><keyword>Carcinoma</keyword><keyword>Cell Differentiation</keyword><keyword>Epithelial Cells/*pathology</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Retrospective Studies</keyword><keyword>Thyroid Neoplasms/*pathology/secondary</keyword><keyword>Time Factors</keyword></keywords><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1530-0285 (Electronic)&#xD;0893-3952 (Linking)</isbn><accession-num>21804527</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 Using more rigorous criteria, namely invasion of tumor cells through a vessel wall as well as thrombus formation in association with tumor, this group demonstrated that over one-third of tumors that fulfilled these criteria had distant metastases. ADDIN EN.CITE <EndNote><Cite><Author>Mete</Author><Year>2011</Year><RecNum>22</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117138">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mete, O.</author><author>Asa, S. L.</author></authors></contributors><auth-address>Department of Pathology, University Health Network, Toronto, Ontario, Canada. Ozgur.Mete2@uhn.on.ca</auth-address><titles><title>Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation</title><secondary-title>Mod Pathol</secondary-title></titles><periodical><full-title>Mod Pathol</full-title></periodical><pages>1545-52</pages><volume>24</volume><number>12</number><edition>2011/08/02</edition><keywords><keyword>Adenocarcinoma, Follicular</keyword><keyword>Artifacts</keyword><keyword>Autopsy</keyword><keyword>Biopsy</keyword><keyword>Blood Vessels/*pathology</keyword><keyword>Carcinoma</keyword><keyword>Cell Differentiation</keyword><keyword>Epithelial Cells/*pathology</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Retrospective Studies</keyword><keyword>Thyroid Neoplasms/*pathology/secondary</keyword><keyword>Time Factors</keyword></keywords><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1530-0285 (Electronic)&#xD;0893-3952 (Linking)</isbn><accession-num>21804527</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 These rigid criteria are also highly predictive of aggressive disease in medullary thyroid carcinoma. 4 While these more rigid criteria require validation from additional studies, they set the framework for the minimal criteria for unequivocal and meaningful vascular invasion, to reiterate: invasion of tumor through a vessel wall accompanied by fibrin thrombus. It is acknowledged that the risk of metastasis when these criteria are not fulfilled by a focus in vessels is not entirely absent5 Additionally, some investigators have suggested that the number of foci of vascular invasion has prognostic impact as well. 6-8 In some studies, encapsulated follicular carcinoma, oncocytic variant with 4 or more foci of vascular invasion, has a significant recurrence rate (47%) even if the foci of angioinvasion are microscopic. 7 On the other hand, another study showed that follicular oncocytic (Hürthle cell) carcinomas with a total of 2 foci of capsular/vascular invasion did not recur after a long follow-up. 8 Moreover, in a series of 4000 thyroid carcinomas of follicular epithelial origin, angioinvasive differentiated thyroid carcinomas that developed distant metastases revealed predominantly a single focus of angioinvasion, and there were no more than 2 foci of vascular invasion. ADDIN EN.CITE <EndNote><Cite><Author>Mete</Author><Year>2011</Year><RecNum>22</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117138">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mete, O.</author><author>Asa, S. L.</author></authors></contributors><auth-address>Department of Pathology, University Health Network, Toronto, Ontario, Canada. Ozgur.Mete2@uhn.on.ca</auth-address><titles><title>Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation</title><secondary-title>Mod Pathol</secondary-title></titles><periodical><full-title>Mod Pathol</full-title></periodical><pages>1545-52</pages><volume>24</volume><number>12</number><edition>2011/08/02</edition><keywords><keyword>Adenocarcinoma, Follicular</keyword><keyword>Artifacts</keyword><keyword>Autopsy</keyword><keyword>Biopsy</keyword><keyword>Blood Vessels/*pathology</keyword><keyword>Carcinoma</keyword><keyword>Cell Differentiation</keyword><keyword>Epithelial Cells/*pathology</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Retrospective Studies</keyword><keyword>Thyroid Neoplasms/*pathology/secondary</keyword><keyword>Time Factors</keyword></keywords><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1530-0285 (Electronic)&#xD;0893-3952 (Linking)</isbn><accession-num>21804527</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 Thus, the use of appropriate criteria seems to be more critical than the number of involved vessels. ADDIN EN.CITE <EndNote><Cite><Author>Mete</Author><Year>2011</Year><RecNum>22</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117138">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mete, O.</author><author>Asa, S. L.</author></authors></contributors><auth-address>Department of Pathology, University Health Network, Toronto, Ontario, Canada. Ozgur.Mete2@uhn.on.ca</auth-address><titles><title>Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation</title><secondary-title>Mod Pathol</secondary-title></titles><periodical><full-title>Mod Pathol</full-title></periodical><pages>1545-52</pages><volume>24</volume><number>12</number><edition>2011/08/02</edition><keywords><keyword>Adenocarcinoma, Follicular</keyword><keyword>Artifacts</keyword><keyword>Autopsy</keyword><keyword>Biopsy</keyword><keyword>Blood Vessels/*pathology</keyword><keyword>Carcinoma</keyword><keyword>Cell Differentiation</keyword><keyword>Epithelial Cells/*pathology</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Retrospective Studies</keyword><keyword>Thyroid Neoplasms/*pathology/secondary</keyword><keyword>Time Factors</keyword></keywords><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1530-0285 (Electronic)&#xD;0893-3952 (Linking)</isbn><accession-num>21804527</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 Figure 3. Vascular invasion (VI): Schematic drawing for the interpretation of the presence or absence of significant VI. The diagram depicts a follicular neoplasm (green) surrounded by a fibrous capsule (tan). The driving concepts behind significant VI are penetration through the vessel wall and a reaction to the vascular deposit, namely thrombus formation, which may range from subtle and fibrinoid in nature to large and heavily organized. ADDIN EN.CITE <EndNote><Cite><Author>Mete</Author><Year>2011</Year><RecNum>22</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117138">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mete, O.</author><author>Asa, S. L.</author></authors></contributors><auth-address>Department of Pathology, University Health Network, Toronto, Ontario, Canada. Ozgur.Mete2@uhn.on.ca</auth-address><titles><title>Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation</title><secondary-title>Mod Pathol</secondary-title></titles><periodical><full-title>Mod Pathol</full-title></periodical><pages>1545-52</pages><volume>24</volume><number>12</number><edition>2011/08/02</edition><keywords><keyword>Adenocarcinoma, Follicular</keyword><keyword>Artifacts</keyword><keyword>Autopsy</keyword><keyword>Biopsy</keyword><keyword>Blood Vessels/*pathology</keyword><keyword>Carcinoma</keyword><keyword>Cell Differentiation</keyword><keyword>Epithelial Cells/*pathology</keyword><keyword>Humans</keyword><keyword>Immunohistochemistry</keyword><keyword>Neoplasm Invasiveness</keyword><keyword>Predictive Value of Tests</keyword><keyword>Prognosis</keyword><keyword>Retrospective Studies</keyword><keyword>Thyroid Neoplasms/*pathology/secondary</keyword><keyword>Time Factors</keyword></keywords><dates><year>2011</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1530-0285 (Electronic)&#xD;0893-3952 (Linking)</isbn><accession-num>21804527</accession-num><urls><related-urls><url> [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 A through C represent scenarios where tumor in vessels are not counted as VI. A. Free-floating irregular tumor fragments often result from artifactual displacement. B. Tumor bulging and indenting the vessel wall does not count as VI. C. Endothelialized tumor floating in an intracapsular vessel may result from tangential sectioning of tumor bulging into a vessel, often at a branch or bifurcation. These findings can however prompt deeper levels (at least by 3) to exclude definitive VI (see E through G).**** D represents a common but contentious scenario among experts, in light of these new proposed criteria for significant VI. This endothelialized tumor deposit is juxtaposed to the vessel wall. As this is somewhat similar to C, and there is no obvious thrombus, technically this would not count as significant VI. One counterargument is that the endothelialized appearance represents “organization” of a tumor thrombus and is thus still significant. While deeper levels may help, this scenario may still be considered a “judgment call” based on current level of evidence. E through G represent unequivocal VI. E. Tumor is juxtaposed to vessel wall and is associated with a thrombus. F. Tumor penetrating vessel wall also demonstrating thrombus formation at its neck. G. Tumor fragments in intermingled with an organized thrombus and adherent to vessel wall. Note: While there is no standard definition of “deeper levels,” generally, each level is at a certain interval (ie, 3 serial sections deeper or 15-micron intervals) below the original H&E rather than an immediate serial section. Original concept for schematic from Fletcher CDM, ed. Diagnostic Histopathology of Tumours. 3rd ed. Edinburgh; Churchill Livingstone Elsevier; 2007. Modified with permission. ? Elsevier.References:1.Rosai J, Carcangiu ML, DeLellis RA. Atlas of Tumor Pathology. Tumors of the Thyroid Gland. Vol 5. 3rd ed. Washington DC: Armed Forces Institute of Pathology; 1992.2.Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011;24(12):1545-1552.3.Chan JK. The thyroid gland. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumours. Edinburgh: Churchill Livingstone Elsevier; 2007:1018.4.Erovic BM, Kim D, Cassol C, et al. Prognostic and predictive markers in medullary thyroid carcinoma. Endocr Pathol. 2012;23(4):232-242.5.Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess CS. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer. 2001;91(3):505-524.6.Collini P, Sampietro G, Pilotti S. Extensive vascular invasion is a marker of risk of relapse in encapsulated non- Hürthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up. Histopathology. 2004;44(1):35-39.7.Ghossein RA, Hiltzik DH, Carlson DL, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer. 2006;106(8):1669-1676.8.Stojadinovic A, Ghossein RA, Hoos A, et al. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001;19(10):2616-2625.K. Extrathyroidal ExtensionExtrathyroidal extension refers to involvement of the perithyroidal tissues by a primary thyroid cancer. Since the thyroid gland does not have a well-defined capsule, 1 the definition of extrathyroidal extension has been problematic and subjective. On gross examination, the capsule may appear complete, but evidence has shown that microscopically the capsule is focally incomplete or absent in a majority of thyroid glands evaluated at autopsy. 2 The perithyroidal tissues include sizable blood vessels as well as small peripheral nerves and are continuous with the pretracheal fascia. ADDIN EN.CITE <EndNote><Cite><Author>Standring</Author><Year>2005</Year><RecNum>33</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>33</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117139">33</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Standring, S.</author></authors><secondary-authors><author>Standring, S.</author></secondary-authors></contributors><titles><title>Thyroid gland</title><secondary-title>Gray&apos;s anatomy: the anatomical basis of clinical practice</secondary-title></titles><pages>560-564</pages><dates><year>2005</year></dates><pub-location>Edinburgh</pub-location><publisher>Elsevieer Churchill Livingstone</publisher><urls></urls></record></Cite></EndNote>3 Extension into adipose tissue is a problematic criterion if used alone, given the fact that adipose tissue can be found within the thyroid gland proper under normal conditions and also may be a component of a variety of thyroid lesions including carcinomas.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HbmVwcDwvQXV0aG9yPjxZZWFyPjE5ODk8L1llYXI+PFJl

Y051bT4zNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjI2

LDM1PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MzQ8L3JlYy1udW1i

ZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwczJ3d2RzZnJhMnI1ZWU5emFz

eHM1dDh6d2R3eHJzd2U1eGEiIHRpbWVzdGFtcD0iMTQ3MzExNzEzOSI+MzQ8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkduZXBwLCBELiBSLjwvYXV0aG9yPjxhdXRob3I+

T2dvcnphbGVrLCBKLiBNLjwvYXV0aG9yPjxhdXRob3I+SGVmZmVzcywgQy4gUy48L2F1dGhvcj48

L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBhdGhv

bG9neSwgU3QuIExvdWlzIFVuaXZlcnNpdHkgU2Nob29sIG9mIE1lZGljaW5lLCBNaXNzb3VyaS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5GYXQtY29udGFpbmluZyBsZXNpb25zIG9mIHRo

ZSB0aHlyb2lkIGdsYW5kPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFtIEogU3VyZyBQYXRob2w8

L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5BbSBKIFN1

cmcgUGF0aG9sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NjA1LTEyPC9wYWdlcz48

dm9sdW1lPjEzPC92b2x1bWU+PG51bWJlcj43PC9udW1iZXI+PGVkaXRpb24+MTk4OS8wNy8wMTwv

ZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QWRpcG9zZSBUaXNzdWUvKnBhdGhvbG9neTwva2V5

d29yZD48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3Jk

PjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+

RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkdvaXRlci9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdv

cmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxl

IEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+VGh5cm9pZCBEaXNlYXNlcy8qcGF0aG9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPlRoeXJvaWQgR2xhbmQvKnBhdGhvbG9neTwva2V5d29yZD48a2V5d29yZD5U

aHlyb2lkIE5lb3BsYXNtcy9wYXRob2xvZ3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHll

YXI+MTk4OTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2Rh

dGVzPjxpc2JuPjAxNDctNTE4NSAoUHJpbnQpJiN4RDswMTQ3LTUxODUgKExpbmtpbmcpPC9pc2Ju

PjxhY2Nlc3Npb24tbnVtPjI2NjA2MTE8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJs

cz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjY2MDYxMTwvdXJsPjwv

cmVsYXRlZC11cmxzPjwvdXJscz48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0Np

dGU+PENpdGU+PEF1dGhvcj5Sb3NhaTwvQXV0aG9yPjxZZWFyPjE5OTI8L1llYXI+PFJlY051bT4y

NTwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MjU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5

cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwczJ3d2RzZnJhMnI1ZWU5emFzeHM1dDh6d2R3eHJzd2U1

eGEiIHRpbWVzdGFtcD0iMTQ3MzExNzEzOCI+MjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5

cGUgbmFtZT0iQm9vayI+NjwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlJvc2FpLCBKLjwvYXV0aG9yPjxhdXRob3I+Q2FyY2FuZ2l1LCBNLkwuPC9hdXRob3I+PGF1dGhv

cj5EZUxlbGxpcywgUi5BLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVz

Pjx0aXRsZT5BdGxhcyBvZiB0dW1vciBwYXRob2xvZ3kuIFR1bW9ycyBvZiB0aGUgdGh5cm9pZCBn

bGFuZC48L3RpdGxlPjwvdGl0bGVzPjx2b2x1bWU+RmFzY2ljbGUgNTwvdm9sdW1lPjxlZGl0aW9u

PjNyZDwvZWRpdGlvbj48ZGF0ZXM+PHllYXI+MTk5MjwveWVhcj48L2RhdGVzPjxwdWItbG9jYXRp

b24+V2FzaGluZ3RvbiBELkMuPC9wdWItbG9jYXRpb24+PHB1Ymxpc2hlcj5Bcm1lZCBGb3JjZXMg

SW5zdGl0dXRlIG9mIFBhdGhvbG9neTwvcHVibGlzaGVyPjx1cmxzPjwvdXJscz48L3JlY29yZD48

L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HbmVwcDwvQXV0aG9yPjxZZWFyPjE5ODk8L1llYXI+PFJl

Y051bT4zNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjI2

LDM1PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MzQ8L3JlYy1udW1i

ZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwczJ3d2RzZnJhMnI1ZWU5emFz

eHM1dDh6d2R3eHJzd2U1eGEiIHRpbWVzdGFtcD0iMTQ3MzExNzEzOSI+MzQ8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkduZXBwLCBELiBSLjwvYXV0aG9yPjxhdXRob3I+

T2dvcnphbGVrLCBKLiBNLjwvYXV0aG9yPjxhdXRob3I+SGVmZmVzcywgQy4gUy48L2F1dGhvcj48

L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBhdGhv

bG9neSwgU3QuIExvdWlzIFVuaXZlcnNpdHkgU2Nob29sIG9mIE1lZGljaW5lLCBNaXNzb3VyaS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5GYXQtY29udGFpbmluZyBsZXNpb25zIG9mIHRo

ZSB0aHlyb2lkIGdsYW5kPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFtIEogU3VyZyBQYXRob2w8

L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5BbSBKIFN1

cmcgUGF0aG9sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NjA1LTEyPC9wYWdlcz48

dm9sdW1lPjEzPC92b2x1bWU+PG51bWJlcj43PC9udW1iZXI+PGVkaXRpb24+MTk4OS8wNy8wMTwv

ZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QWRpcG9zZSBUaXNzdWUvKnBhdGhvbG9neTwva2V5

d29yZD48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3Jk

PjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2hpbGQ8L2tleXdvcmQ+PGtleXdvcmQ+

RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkdvaXRlci9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdv

cmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxl

IEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+VGh5cm9pZCBEaXNlYXNlcy8qcGF0aG9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPlRoeXJvaWQgR2xhbmQvKnBhdGhvbG9neTwva2V5d29yZD48a2V5d29yZD5U

aHlyb2lkIE5lb3BsYXNtcy9wYXRob2xvZ3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHll

YXI+MTk4OTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2Rh

dGVzPjxpc2JuPjAxNDctNTE4NSAoUHJpbnQpJiN4RDswMTQ3LTUxODUgKExpbmtpbmcpPC9pc2Ju

PjxhY2Nlc3Npb24tbnVtPjI2NjA2MTE8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJs

cz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjY2MDYxMTwvdXJsPjwv

cmVsYXRlZC11cmxzPjwvdXJscz48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0Np

dGU+PENpdGU+PEF1dGhvcj5Sb3NhaTwvQXV0aG9yPjxZZWFyPjE5OTI8L1llYXI+PFJlY051bT4y

NTwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MjU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5

cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJwczJ3d2RzZnJhMnI1ZWU5emFzeHM1dDh6d2R3eHJzd2U1

eGEiIHRpbWVzdGFtcD0iMTQ3MzExNzEzOCI+MjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5

cGUgbmFtZT0iQm9vayI+NjwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlJvc2FpLCBKLjwvYXV0aG9yPjxhdXRob3I+Q2FyY2FuZ2l1LCBNLkwuPC9hdXRob3I+PGF1dGhv

cj5EZUxlbGxpcywgUi5BLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVz

Pjx0aXRsZT5BdGxhcyBvZiB0dW1vciBwYXRob2xvZ3kuIFR1bW9ycyBvZiB0aGUgdGh5cm9pZCBn

bGFuZC48L3RpdGxlPjwvdGl0bGVzPjx2b2x1bWU+RmFzY2ljbGUgNTwvdm9sdW1lPjxlZGl0aW9u

PjNyZDwvZWRpdGlvbj48ZGF0ZXM+PHllYXI+MTk5MjwveWVhcj48L2RhdGVzPjxwdWItbG9jYXRp

b24+V2FzaGluZ3RvbiBELkMuPC9wdWItbG9jYXRpb24+PHB1Ymxpc2hlcj5Bcm1lZCBGb3JjZXMg

SW5zdGl0dXRlIG9mIFBhdGhvbG9neTwvcHVibGlzaGVyPjx1cmxzPjwvdXJscz48L3JlY29yZD48

L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE.DATA 4,5 Given this state of variability, microscopic extrathyroidal extension that is not grossly evident is no longer a criterion for upstaging. The pT3b stage is now defined by gross extrathyroidal extension into skeletal muscle, which then necessitates review of macroscopic, intraoperative, and radiologic findings. As such, a thorough gross examination and review of the operative and radiologic findings are now essentially required to document the “gross” extrathyroidal extension required to upstage a tumor. Recent evidence also suggests that the identification of microscopic extra-thyroidal extension is associated with reduced disease-free survival irrespective of tumor size 6. While other studies are needed to confirm this finding, documentation of microscopic strap muscle invasion may help to assist the dynamic risk stratification of patients with differentiated thyroid carcinoma that have otherwise low risk disease. However, the identification of microscopic strap muscle invasion should not be used to upstage the tumor as pT3b in the absence of gross or intraoperative evidence of strap muscle invasion. References:1.Mete O, Rotstein L, Asa SL. Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol. 2010;17(2):386-391.2.Komorowski RA, Hanson GA. Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol. 1988;19(6):689-696.3.Standring S. Thyroid gland. In: Standring S, ed. Gray's Anatomy: The Anatomical Basis of Clinical Practice. Edinburgh: Elsevieer Churchill Livingstone; 2005:560-564.4.Rosai J, Carcangiu ML, DeLellis RA. Atlas of Tumor Pathology. Tumors of the Thyroid Gland. Vol 5. 3rd ed. Washington DC: Armed Forces Institute of Pathology; 1992.5.Gnepp DR, Ogorzalek JM, Heffess CS. Fat-containing lesions of the thyroid gland. Am J Surg Pathol. 1989;13(7):605-612.6.Tran B, Roshan D, Abraham E, et al. An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2018;103(6):2199-2206.L. Lymph NodesRegional Lymph NodesRegional lymph node spread from thyroid cancer is common but of less prognostic significance in patients with well-differentiated tumors (papillary) than in medullary cancers. The adverse prognostic influence of lymph node metastasis in patients with differentiated carcinomas is observed only in the older age group. ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1 In comparison to macrometastatic disease, micrometastases in thyroid cancer of follicular cell differentiation are of even less clinical value. Based on a few studies to date, micrometastasis does not appear to confer an increased risk of locoregional recurrence as compared to node-negative patients and does not likely warrant more aggressive intervention.2,3 The same holds true for isolated tumor cells and psammomatous calcifications (psammoma bodies) only in lymph nodes. Reporting of “psammoma bodies only” in lymph nodes is not well defined. While indolent, they do indicate capacity for lymphatic spread and are considered pN1a. On the other end of the spectrum, larger size of lymph node metastases can confer a higher risk of locoregional recurrence, and the American Thyroid Association thus advocates reporting of the size of the largest metastatic focus.4 Currently, there are no validated differentiated thyroid carcinoma specific cut-offs for size on for macro- or micrometastases. ADDIN EN.CITE <EndNote><Cite><Author>Rosen</Author><Year>2017</Year><RecNum>46</RecNum><DisplayText><style face="superscript">1,2</style></DisplayText><record><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473120927">46</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Rosen, J.E.</author><author>Lloyd, R.V.</author><author>Brierley, J.D.</author><author>Grogan, R.H.</author><author>Haddad, R.</author><author>Hunt, J.L.</author><author>Ridge, J.A.</author><author>Seethala, R.R.</author><author>Sosa, J.A.</author><author>Subramaniam, R.M.</author><author>Wang, T.S.</author><author>Wirth, L.J. </author><author>Perrier, N.D.</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- Medullary</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1,5 However, several experts and the American Thyroid Association adopted the cut-off of 2 mm to define micrometastasis6. Classification of Neck Dissection1.Radical neck dissection2.Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared3.Selective neck dissection (SND), as specified by the surgeon, with levels and sublevels designated (see Figure 3),7,8 such as:a.Supraomohyoid neck dissectionb.Posterolateral neck dissectionc.Lateral neck dissectiond.Central compartment neck dissection4.Superselective neck dissection, as specific by the surgeon5. Extended radical neck dissection, as specified by the surgeonThe first echelon of nodal metastasis consists of the paralaryngeal, paratracheal, and prelaryngeal (Delphian) nodes adjacent to the thyroid gland in the central compartment of the neck, generally described as level VI. ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1 Metastases secondarily involve the mid- and lower jugular, the supraclavicular, and (much less commonly) the upper deep jugular and spinal accessory lymph nodes. ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1 Lymph node metastasis to submandibular and submental lymph nodes is very rare. Upper mediastinal (level VII) nodal spread occurs frequently both anteriorly and posteriorly. Retropharyngeal nodal metastasis may be seen, usually in the presence of extensive lateral cervical metastasis. ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1 Bilateral nodal spread is common. The components of the N category are described as follows: first echelon (perithyroidal/central compartment/level VI and/or superior mediastinal/level VII), or N1a; and lateral cervical/level I-V, or N1b. Commonly utilized surgical techniques for compartmental dissection often result in varying portions of the central compartment being resected en bloc with the thyroidectomy specimen, thus “perithyroidal” lymph nodes seen here are counted towards the N status of the patient (in addition to other parts formally labeled as central compartment or level VI).9 The lymph node metastasis should also be described according to the level of the neck that is involved. In comparison to metastatic head and neck squamous cell carcinoma, the risk for increased locoregional disease and distant metastasis in the presence of extranodal extension of thyroid cancer is not as widely validated, although several studies have shown an increase risk for distant metastases and death in the presence of extranodal extension.4,10,11 Therefore, as a recommendation, the pathologist should comment on the presence or absence of extranodal extension. Nodal metastases from medullary thyroid cancer carry a much more ominous prognosis, although they follow a similar pattern of spread. For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 4. 12Figure 4. The 6 sublevels of the neck for describing the location of lymph nodes within levels I, II, and V. Level IA, submental group; level IB, submandibular group; level IIA, upper jugular nodes along the carotid sheath, including the subdigastric group; level IIB, upper jugular nodes in the submuscular recess; level VA, spinal accessory nodes; and level VB, the supraclavicular and transverse cervical nodes. From Flint PW, et al, eds. Cummings Otolaryngology: Head and Neck Surgery. 5th ed. Philadelphia, PA; Saunders: 2010. Reproduced with permission. ? Elsevier.In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and on the details of the local anatomy in the specimens they submit for examination, or in other ways orient those specimens for pathologists. 7,8If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.Level I. Submental Group (Sublevel IA) Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.Submandibular Group (Sublevel IB) Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.Level II. Upper Jugular Group (Sublevels IIA and IIB)Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.Level III. Middle Jugular Group Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.Level IV. Lower Jugular Group Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.Level V. Posterior Triangle Group (Sublevels VA and VB)This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.Level VI. Anterior (Central) CompartmentLymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia. Level VII. Superior Mediastinal Lymph NodesMetastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases. Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.Lymph Node NumberHistologic examination of a selective neck dissection specimen will ordinarily include 6 or more lymph nodes. Histologic examination of a radical or modified radical neck dissection specimen will ordinarily include 10 or more lymph nodes in the untreated neck. ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1 Special Procedures for Lymph NodesAt the current time, no additional special techniques should be used other than routine histology for the assessment of nodal metastases (ie, sentinel lymph node-type protocols are not advocated). However, confirmation by immunohistochemical staining, including TTF-1, PAX8, and thyroglobulin for papillary carcinoma, calcitonin and monoclonal CEA along with neuroendocrine markers (eg, chromogranins, synaptophysin) for medullary carcinoma, may be required.References:1.Tuttle RM, Morris LF, Haugen BR, et al. Thyroid- differentiated and anaplastic carcinoma. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.2.Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer: an important finding? Surg Oncol. 2008;17(3):253-258.3.Urken ML, Mechanick JI, Sarlin J, Scherl S, Wenig BM. Pathologic reporting of lymph node metastases in differentiated thyroid cancer: a call to action for the College of American Pathologists. Endocr Pathol. 2014;25(3):214-218.4.Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144-1152.5.Rosen JE, Lloyd RV, Brierley JD, et al. Thyroid-medullary. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.6.Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.7.Robbins KT, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW. Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology. Arch Otolaryngol Head Neck Surg. 1991;117(6):601-605.8.Robbins KT, Shaha AR, Medina JE, et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008;134(5):536-538.9.Carty SE, Cooper DS, Doherty GM, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153-1158.10.Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis: a good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999;86(5):842-849.11.Lango M, Flieder D, Arrangoiz R, et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid. 2013;23(9):1099-1105.12.Robbins KT, Samant S, Ronen O. Neck Dissection. In: Flint PW, Haughey BH, Lund VJ, et al, eds. Cummings Otolaryngology: Head and Neck Surgery. 5th ed. Philadelphia, PA: Saunders; 2005:1702-1725.M. TNM and Stage GroupingsAccording to the American Joint Committee on Cancer (AJCC) ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1 the TNM stage groupings for papillary and follicular carcinomas and variants thereof are stratified by age, including patients under 55 years of age and patients 55 years and older, as well as the individual TNM parameters. Age is not used to stratify medullary thyroid carcinoma into stage groups. ADDIN EN.CITE <EndNote><Cite><Author>Rosen</Author><Year>2017</Year><RecNum>46</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473120927">46</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Rosen, J.E.</author><author>Lloyd, R.V.</author><author>Brierley, J.D.</author><author>Grogan, R.H.</author><author>Haddad, R.</author><author>Hunt, J.L.</author><author>Ridge, J.A.</author><author>Seethala, R.R.</author><author>Sosa, J.A.</author><author>Subramaniam, R.M.</author><author>Wang, T.S.</author><author>Wirth, L.J. </author><author>Perrier, N.D.</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- Medullary</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>2Undifferentiated (anaplastic) carcinoma is always assigned stage IV and subgrouped into IVA, IVB, IVC by TNM parameters. ADDIN EN.CITE <EndNote><Cite><Author>Tuttle</Author><Year>2017</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="ps2wwdsfra2r5ee9zasxs5t8zwdwxrswe5xa" timestamp="1473117135">1</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Tuttle, R.M.</author><author>Morris, L.F.</author><author>Haugen, B.R. </author><author>Shah, J.P </author><author>Sosa, J.A.</author><author>Rohren, E.</author><author>Subramaniam, R. M.</author><author>Hunt, J.L.</author><author>Perrier, N.D</author></authors><secondary-authors><author>Amin, M.B.</author></secondary-authors></contributors><titles><title>Thyroid- differentiated and anaplastic carcinoma</title><secondary-title>AJCC Cancer Staging Manual</secondary-title></titles><edition>8th</edition><dates><year>2017</year></dates><pub-location>New York, NY</pub-location><publisher>Springer</publisher><urls></urls></record></Cite></EndNote>1 All categories may be subdivided: (a) solitary tumor, (b) multifocal tumor. With multifocal tumors, the most aggressive (typically the largest) one is used for classification. The multifocal designation may be used for tumors of different histologies (ie, a follicular and papillary carcinoma, not just multiple papillary carcinomas). The lymph nodes must be specifically identified to classify regional node involvement.TNM DescriptorsFor identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.The “a” prefix designates the stage determined at autopsy: aTNM.References ADDIN EN.REFLIST 1.Tuttle RM, Morris LF, Haugen BR, et al. Thyroid- differentiated and anaplastic carcinoma. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.2.Rosen JE, Lloyd RV, Brierley JD, et al. Thyroid-medullary. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download